Podcasts about amyotrophic lateral sclerosis als

Discover Lafayette welcomes Dale Clark, Ursula Quoyeser, and Harriet Hoag to discuss the upcoming 4th annual Fin Feather Fur Food Festival ("F5"). This event raises funds for the Team Gleason Foundation, which supports individuals living with Amyotrophic Lateral Sclerosis (“ALS”). Team Gleason, through its diverse and broad-reaching programming, brings assistive technology, equipment, and robust support services into the hands of ALS patients – to help individuals with ALS not just survive but thrive after a devastating diagnosis. Each of our guests has either been personally affected by ALS or has supported a loved one with the disease. Event Details: Date: April 24, 2025 Time: 4:00 PM - 8:00 PM Location: Blackham Coliseum, Lafayette, LA Tickets: $45 Website: https://teamgleason.org/f5/ Attendees can enjoy great food, beer, and wine while supporting a worthy cause. F5 is a cooking competition where teams compete in four categories: Fin, Feather, Fur, and Dessert. Awards will be given to the best dishes, a "People's Choice" winner, and a "Team Showmanship" winner chosen by a panel of judges. Additionally, a silent auction will offer a selection of valuable items. Teams also compete to raise the most funds for Team Gleason, with prizes awarded to top fundraisers. About Team Gleason Foundation: In January 2011, New Orleans Saints star Steve Gleason was diagnosed with ALS. Faced with this devastating diagnosis, Steve embraced a new mission: to show that people with ALS can not only live but thrive and to inspire others facing similar challenges. “People were simply expected to fade away quietly and die, that was not acceptable to me. That is not OK.” Steve and his wife, Michel Varisco, founded Team Gleason, a nonprofit dedicated to helping individuals with ALS lead purposeful and fulfilling lives.  Team Gleason has provided over $55 million in resources to individuals with ALS. Their work includes supplying mobility equipment, power seat elevators, speech-generating devices, and essential home modifications. Personal Impact of Team Gleason: Ursula Quoyeser's Experience Ursula has received significant support from Team Gleason. These resources have been life-changing, enabling her to maintain independence. Ursula reflects on how Team Gleason anticipates needs before they arise, ensuring that people living with ALS receive assistance promptly. One of the most important things that Team Gleason provides is pathways of communication to connect ALS families with each other so that resources that are no longer needed are generously shared. Many of you know Ursula as a superstar Volleyball coach! She is still a superstar and it is an honor to share her story so that the Team Gleason message may be distributed to a wide audience! Harriet Hoag's Journey Harriet's late husband, Monty, was diagnosed with ALS during the height of COVID-19, making the journey even more isolating. Doctors struggled to diagnose him, but Harriet's own research led them to Baylor Hospital, where they received confirmation. She credits Team Gleason for providing invaluable resources such as a speech-generating device that allowed Monty to communicate with their granddaughter even in his final days. Dale Clark's Commitment After being diagnosed with ALS, Dale was inspired to help others in the ALS community. Witnessing the challenges faced by fellow patients at his clinic in Houston, he saw the opportunity to make a difference. His dedication, alongside generous contributions from local companies like Badger Oil and Gas and Service Chevrolet, has helped F5 grow into a major fundraising success. For a more in-depth interview we did in 2024 with Dale and Ursula, listen here. Dale Clark says, "100% of the money goes to Team Gleason. In fact, we tell people to mail their check to Team Gleason so we don't have to handle any money. The Importance of Fundraising: Over the past three years,

Joe was born and raised in Philadelphia, Pennsylvania and since childhood he has loved the Philadelphia Phillies. According to him, “I live and die with the Phillies, no matter where they are in the standings. They have been playing great of late and that makes me happy!” Now a Nashvillian for almost five decades, Joe is also a Tennessee Titans football fan. He has had season tickets since they arrived in Nashville in 1998. Joe is an avid writer and songwriter and became a published children's book author in 1997 with The Molly Books, a four-book series published by Ideal's Children's Books. In 2003, New Leaf Press published G. I. Joe and Lillie: Remembering a Life of Love and Loyalty, an inspirational biography Joe penned about his parents. His song by the same name was included on the Oaks' Colors album, released the same year. A music video of the song reemerged in the summer of 2009 and became a YouTube phenomenon with almost six million views. Joe also wrote the title song for the Oaks' The Journey album, as well as the text for The Oak Ridge Boys' coffee table book, An American Journey, published in 2004. In 2014, New Leaf published Joe's Christmas short story, An Inconvenient Christmas, which was inspired by an Oak Ridge Boys' song from an album by the same name. In September 2010, Journey Press, a division of Sheaf House, released From My Perspective, a collection of Joe's commentaries, stories, and other writings. His book Christmas Miracles, a collection of Christmas short stories and commentaries, originally published in 2008, was updated in 2012. His most recent book, On the Road with The Oak Ridge Boys, was published by Harvest House Publishers in May 2015. For relaxation, Joe retreats to his farm on the Tennessee-Kentucky state line, where he can often be found on his John Deere tractor mowing part of his 350-acres—or sitting on his front porch and playing banjo, an instrument he has played for more than a decade. He plays a step-out lead on the Oaks' Rock of Ages CD. Joe has been singing since he was about four years old and in his mid-teens fell in love with Southern Gospel music harmony. A born-again Christian, he is always quick to give God the credit for everything he has accomplished. He joined the Oaks in 1973, just prior to the group's emergence on the Country music scene. As with the other group members, much of Joe's time has been spent on the road performing, but he found his own way to get the maximum possible enjoyment out of touring. “My life has been simple,” says the Oak who was the principal spokesman on stage for five decades. “I go out there and try to sing the best I can and give them physically and mentally everything I've got. When it's done, I go back to my room or the bus, eat some pizza or sushi, call my Mary, get on my Apple laptop, do a little writing, and say to myself, ‘Hey, I've done what I'm supposed to be doing and I feel great about it.'” Joe and his wife, Mary, have two daughters, Jennifer, and Sabrina; two grandchildren, Breanne and Luke, who recently served in the U.S. Navy; and one great grandson, Noah Chance. They also have four cats, Mitty, Crockett, Barney, and Maggie Mae. In early 2024, Joe announced his retirement from touring due to the onset of a neuromuscular disorder. He passed on to Glory on July 9, 2024, due to complications from Amyotrophic Lateral Sclerosis (ALS). He leaves behind his precious wife, Mary Ann, daughters Jennifer and Sabrina, granddaughter Breanne, grandson Luke, two great grandsons, Chance and Grey, and a sister, Nancy. He is preceded in death by his parents Joseph S. Bonsall Sr. and Lillie Bonsall. A memoir written by Joe in early 2024, entitled I See Myself, will be released in November.

Joe was born and raised in Philadelphia, Pennsylvania and since childhood he has loved the Philadelphia Phillies. According to him, “I live and die with the Phillies, no matter where they are in the standings. They have been playing great of late and that makes me happy!” Now a Nashvillian for almost five decades, Joe is also a Tennessee Titans football fan. He has had season tickets since they arrived in Nashville in 1998. Joe is an avid writer and songwriter and became a published children's book author in 1997 with The Molly Books, a four-book series published by Ideal's Children's Books. In 2003, New Leaf Press published G. I. Joe and Lillie: Remembering a Life of Love and Loyalty, an inspirational biography Joe penned about his parents. His song by the same name was included on the Oaks' Colors album, released the same year. A music video of the song reemerged in the summer of 2009 and became a YouTube phenomenon with almost six million views. Joe also wrote the title song for the Oaks' The Journey album, as well as the text for The Oak Ridge Boys' coffee table book, An American Journey, published in 2004. In 2014, New Leaf published Joe's Christmas short story, An Inconvenient Christmas, which was inspired by an Oak Ridge Boys' song from an album by the same name. In September 2010, Journey Press, a division of Sheaf House, released From My Perspective, a collection of Joe's commentaries, stories, and other writings. His book Christmas Miracles, a collection of Christmas short stories and commentaries, originally published in 2008, was updated in 2012. His most recent book, On the Road with The Oak Ridge Boys, was published by Harvest House Publishers in May 2015. For relaxation, Joe retreats to his farm on the Tennessee-Kentucky state line, where he can often be found on his John Deere tractor mowing part of his 350-acres—or sitting on his front porch and playing banjo, an instrument he has played for more than a decade. He plays a step-out lead on the Oaks' Rock of Ages CD. Joe has been singing since he was about four years old and in his mid-teens fell in love with Southern Gospel music harmony. A born-again Christian, he is always quick to give God the credit for everything he has accomplished. He joined the Oaks in 1973, just prior to the group's emergence on the Country music scene. As with the other group members, much of Joe's time has been spent on the road performing, but he found his own way to get the maximum possible enjoyment out of touring. “My life has been simple,” says the Oak who was the principal spokesman on stage for five decades. “I go out there and try to sing the best I can and give them physically and mentally everything I've got. When it's done, I go back to my room or the bus, eat some pizza or sushi, call my Mary, get on my Apple laptop, do a little writing, and say to myself, ‘Hey, I've done what I'm supposed to be doing and I feel great about it.'” Joe and his wife, Mary, have two daughters, Jennifer, and Sabrina; two grandchildren, Breanne and Luke, who recently served in the U.S. Navy; and one great grandson, Noah Chance. They also have four cats, Mitty, Crockett, Barney, and Maggie Mae. In early 2024, Joe announced his retirement from touring due to the onset of a neuromuscular disorder. He passed on to Glory on July 9, 2024, due to complications from Amyotrophic Lateral Sclerosis (ALS). He leaves behind his precious wife, Mary Ann, daughters Jennifer and Sabrina, granddaughter Breanne, grandson Luke, two great grandsons, Chance and Grey, and a sister, Nancy. He is preceded in death by his parents Joseph S. Bonsall Sr. and Lillie Bonsall. A memoir written by Joe in early 2024, entitled I See Myself, will be released in November.

Osteosarcoma Webinar Series: Osteosarcoma Webinar Series: One of our MIB Agents OutSmarting Osteosarcoma 2024 grant recipients, Dr. Shahana Mahajan, a Professor and Principal Investigator from Hunter College of the City University of New York will provide an overview of her funded work on repurposing drugs for metastatic osteosarcoma. Dr. Mahajan will share the recent findings from her lab on testing the efficacy of Riluzole in osteosarcoma cell lines and patient-derived cell lines. Riluzole is a glutamate-release inhibitor and has been used for Amyotrophic Lateral Sclerosis (ALS) for decades and is being tested for other neurodegenerative disorders. Riluzole has shown promising results in glutamate receptor-expressing melanoma and other cancer types. The Mahajan Lab efforts are invested in establishing Riluzole as a possible treatment option for osteosarcoma for which targeted therapy has not been successful due to lack of oncogenic driver mutations. In their lab, Riluzole has shown efficacy in inhibiting proliferation, migration, and invasive ability of osteosarcoma cells in 11 cell lines and 4 patient-derived lines. Dr. Mahajan earned a Ph.D. from the Indian Institute of Science, a premier Institute in India in the field of Molecular Biology. She did postdoctoral studies at Weill Cornell Medical College in the Department of Pharmacology and at NYU Langone Medical Center in the Department of Biochemistry. She continued her research at NYU Langone Medical Center as a Research Assistant Professor until she joined Hunter College as an Assistant Professor in 2007. At Hunter, she continued her research neuroscience to investigate glutamate-induced excitotoxicity in rat hippocampal neurons. After her lab was lost to Hurricane Sandy, she reinitiated her research in osteosarcoma. In 2015, her lab moved to Belfer Research Building which is a part of Weill Cornell Medical College. She was appointed as an adjunct faculty at Weill Cornell Medical College. After a short presentation on this research, she will take questions from attendees. Share your questions in advance with us at Christina@MIBAgents.org.

Send us a textWhen Benson St. Louis, a strong and active father and husband, began experiencing unusual physical symptoms in 2022, he and his wife, Karol, embarked on a year-long journey of testing and doctor visits. After ruling out various possibilities, they received a heartbreaking diagnosis: Benson had Amyotrophic Lateral Sclerosis (ALS). In this episode, Benson and Karol discuss how they have adjusted to life after the diagnosis and share how their faith has helped them face one of life's most difficult challenges with grace, love, and humor.Mentioned in the Episode:Watch Steve Gleason's speech from the Espy's here.Find Steve Gleason's book here. Thanks for listening to the Embodied Holiness Podcast. We invite you to join the community on Facebook and Instagram @embodiedholiness. You can find all our episodes and more at www.embodiedholiness.com. Embodied Holiness is a ministry of Parkway Heights United Methodist Church in Hattiesburg, MS. If you're in the Hattiesburg area and are looking for a church home, we'd love to meet you and welcome you to the family. You can find out more about Parkway Heights at our website.

In this episode of the Brain & Life podcast, award-winning actor, singer, and advocate Aaron Lazar joins co-host Dr. Daniel Correa to discuss his journey with amyotrophic lateral sclerosis (ALS) and how it has affected his daily outlook on life. Aaron shares about his symptoms, diagnostic journey, and how he is continuing to find hope. Dr. Correa is then joined by Dr. Richard Bedlack, Stewart, Hughes, and Wendt Distinguished Professor of ALS at Duke and director of the Duke ALS Clinic. Dr. Bedlack explains just how he is helping his patients find hope in their ALS journeys while also making realistic plans for the future.   Additional Resources Aaron Lazar's “The Impossible Dream” What is Amyotrophic Lateral Sclerosis (ALS)? A Marathoner on a Quest to End ALS Steve Gleason, ALS Advocate and NFL Veteran, Receives Courage Award   Other Brain & Life Episodes on this Topic Making the Years Count with Brooke Eby, Influencer Living with ALS Finding Strength in ALS Advocacy with Podcaster Lorri Carey Hop on a Cure for ALS with John Driskell Hopkins   We want to hear from you! Have a question or want to hear a topic featured on the Brain & Life Podcast? ·       Record a voicemail at 612-928-6206 ·       Email us at BLpodcast@brainandlife.org   Social Media:   Guests: Aaron Lazar @aaronscottlazar; Dr. Richard Bedlack @stitchingstrength Hosts: Dr. Daniel Correa @neurodrcorrea; Dr. Katy Peters @KatyPetersMDPhD

Send us a textHad the pleasure of speaking with "Dynamite Doll" Bronwyne Billington! Billington is the daughter of the late "Dynamite Kid" Tom Billington, who passed away in 2018. On episode 130, we discussed growing up in a wrestling family, how she reconnected with her father after a long stretch of time, entering the wrestling business, raising awareness of Amyotrophic Lateral Sclerosis (ALS), and more. You can find out more about Billington here:https://www.instagram.com/bronwynejewel/https://x.com/Dynamitedoll84https://www.patreon.com/DynamiteDoll?utm_campaign=creatorshare_creatorCheck out the Dynamite Kid IG page here:https://www.instagram.com/officialdynamitekid/Are you a pro wrestler and have done community service and/or charity work? E-mail the podcast at wrestlingwithheart@yahoo.com and tell us if you would be interested in being interviewed.Follow us on:Facebook: Wrestling with Heart with Stanley KarrX: @wwhwskInstagram: @wrestlingwithheartThreads: @wrestlingwithheartHear Wrestling with Heart on Apple Podcasts: https://podcasts.apple.com/us/podcast...Hear Wrestling with Heart on Spotify: https://open.spotify.com/show/46cviL5...Hear Wrestling with Heart on iHeartRadio: https://www.iheart.com/podcast/269-wr...Hear Wrestling with Heart on Google Podcasts: https://podcasts.google.com/search/Wr...Donate to my Patreon and subscribe to my content here: https://www.patreon.com/user?u=84502525Support the show

Amyotrophic Lateral Sclerosis (ALS), Multiple Sclerosis (MS) are they one and the same? Is ALS and MS sometimes caused by caused by the Herpes Zoster Virus? Epstein Barr Virus (EBV) and Cytomeglavirus (CMV), which are forms of Herpes virus are they related. Yes these all can be cured! In this episode we will discuss all the possibilities that these life taking and life changing diseases may all be related and treatable in a safe, though unconventional way.

Amyotrophic Lateral Sclerosis (ALS), Multiple Sclerosis (MS) are they one and the same? Is ALS and MS sometimes caused by caused by the Herpes Zoster Virus? Epstein Barr Virus (EBV) and Cytomeglavirus (CMV), which are forms of Herpes virus are they related. Yes these all can be cured! In this episode we will discuss all the possibilities that these life taking and life changing diseases may all be related and treatable in a safe, though unconventional way.

Amyotrophic Lateral Sclerosis (ALS) is a progressive nervous system disease that destroys nerve cells, mostly in the Central Nervous Systems (Brain and Spinal Cord). It affects control of the voluntary muscle movements needed to move, speak, eat and breathe. Listen to this very interesting podcast where Dr. Zahra Figueredo explains how the Stem Cell Treatment can help to stop the progresiveness of this condition. #stemcells #StemCellTreatment #StemCellTherapy #ALS #AmyotrophicLateralSclerosis __________________________________________________ Could Dr. Zahra's Natural and Unique Stem Cell Therapy Transform Your Life? "My heart and soul sing when we see what an incredible impact we can make on the lives of our patients and their families with our natural and comprehensive stem cell therapies." Dr. Zahra Figueredo. Canadian Dr. Zahra Figueredo has successfully treated 1,000+ patients from the USA and Canada suffering with hundreds of different health problems in her Stem Cell Healing Institute in Guatemala - 'the land of eternal Spring' - with her safe, comprehensive, non-surgical and innovative stem cell therapies. It's important to note that Dr. Zahra's powerful stem cell combination therapy is NOT available anywhere in the USA or Canada. What To Do Now? New Patient? - Learn how Dr. Zahra's combined stem cell healing could transform your life. Please send us an email. info@stemcellhealinginstitute.com For more information on stem cell treatment please visit our website

Guest: Emily Kornman, MCD, CCC-SLP - Emily brings Team Gleason to you in this one-hour conversational audio course podcast. Team Gleason is a 5013(c)(3) organization founded in 2011 by Steve and Michel Gleason - Team Gleason has provided over $40 million in adventure, technology, equipment, and care services to people living with Amyotrophic Lateral Sclerosis (ALS) and countless others through advocacy and support. Emily highlights how Team Gleason supports people with ALS and their families with an interdisciplinary approach. She describes how SLPs can support speech, swallowing, voice preservation, and AAC options to empower people with ALS to live purposeful lives.

This week on the Life Science Success Podcast, my guest is Dr. Tiago Reis Marques Dr. Marques is a psychiatrist and currently the Chief Executive Officer of Pas i thea Therapeutics. Pasithea is developing new molecular entities for the treatment of CNS disorders, including Amyotrophic Lateral Sclerosis (ALS) and Multiple Sclerosis, Neurofibromatosis type 1 and Noonan syndrome.   On this episode of Life Science Success, Don Davis interviews Dr. Tiago Reis Marques, the CEO of PACEA Therapeutics. They discuss Dr. Marques's journey in psychiatry, the company's focus on CNS disorders, their pipeline of drugs targeting neurological conditions like schizophrenia and ALS, and the impact of their research on rare disorders like neurofibromatosis type one. The conversation also touches on leadership advice, inspiration, concerns about global issues, and what excites them. Dr. Tiago Reis Marques, a psychiatrist, is the CEO of Pasithea Therapeutics, a company focused on central nervous system (CNS) disorders. His background in medical research and his transition from academia to biotech were driven by a desire to apply his knowledge to develop treatments that benefit patients. Pasithea Therapeutics, co-founded with Professor Steinman from Stanford, aims to create innovative therapies for unmet needs in CNS disorders. The company's approach balances new drugs targeting novel mechanisms of action with known drugs repurposed for new applications. One of the company's focuses is on neurofibromatosis type one, a disorder affecting around 100,000 patients in the US, highlighting the company's commitment to tackling rare and challenging diseases with significant unmet needs. Marques emphasizes the importance of precision psychiatry and targeting specific subtypes of disorders, drawing parallels to how cancer treatments have evolved to focus on specific biomarkers and subtypes, reflecting a broader trend towards personalized medicine. His experiences and work in brain imaging, specifically with positron emission tomography (PET) and psychopharmacology, underscore his multidisciplinary approach to understanding and treating CNS disorders, leveraging his academic background to inform his leadership and strategic direction at Pasithea Therapeutics.

Stephanie Morales-Beaulieu will never forget the day her dad called to tell her he had been diagnosed with Amyotrophic Lateral Sclerosis (ALS). The doctor had given him three to five years to live. This propelled Stephanie into a season she did not think she would survive. After experiencing what a little bit of trust in God's faithfulness can accomplish, Morales-Beaulieu was compelled to share this message, and her father's life, legacy and love for Jesus in her first book, Anything But Ordinary.  Today on Connections, Stephanie shares her family's story and how it has helped grow her faith.See omnystudio.com/listener for privacy information.

Welcome to this episode of The Genetics Podcast as we host Dr. Michael Benatar, a preeminent figure in the fight against Amyotrophic Lateral Sclerosis (ALS). Michael is a Professor of Neurology, the Chief of the Neuromuscular Division, and the Executive Director of the ALS Center at the University of Miami's Miller School of Medicine. Tune in as he and Patrick discuss research and treatment for presymptomatic gene carriers and other people at risk for ALS, as well as the future of ALS research.

Parkinson's is the second most common neurological disease after Alzheimer's and affects about one percent of people over sixty. The symptoms develop slowly. These include rigidity, a characteristic resting tremor, and movement dysfunction with walking problems. As it progresses, problems with sleep, thinking, and eventually dementia may occur. Survival after diagnosis is seven to fifteen years. Like many neurological problems, PD is a syndrome with recognized clinical characteristics rather than a clearly defined disease with definitive lab tests and treatments. Genetics have been weakly implicated, but cannot be the primary cause because the incidence is skyrocketing. Parkinson's (PD), Autism, Alzheimer's (AD), Multiple Sclerosis (MS), and Amyotrophic Lateral Sclerosis (ALS or Lou Gehrig's disease) are likely caused by toxins. Ken Stoller lays out some of the evidence implicating glyphosate in Incurable Me: Why the Best Medical Research Does Not Make It into Clinical Practice (2015). US government databases were searched for… crop data, glyphosate application data and disease epidemiological data. Correlation analyses were then performed on a total of 22 diseases… Correlation coefficients are highly significant (< 10–5) between glyphosate applications and hypertension (R = 0.923), stroke (R = 0.925), diabetes prevalence (R = 0.971), diabetes incidence (R = 0.935), obesity (R = 0.962), lipoprotein metabolism disorder (R = 0.973), Alzheimer's (R = 0.917), senile dementia (R = 0.994), Parkinson's (R = 0.875), multiple sclerosis (R = 0.828), autism (R = 0.989), inflammatory bowel disease (R = 0.938), intestinal infections (R = 0.974), end stage renal disease (R = 0.975), acute kidney failure (R = 0.978), cancers of the thyroid (R = 0.988), liver (R = 0.960), bladder (R = 0.981), pancreas (R = 0.918), kidney (R = 0.973) and myeloid leukaemia (R = 0.878). He also says that many other toxins increase the chances of developing PD. Paraquat exposure, for example, increases the risk 2.5-fold. Ken goes on:The latest research shows that AD, PD, and ALS share a common, or at least overlapping, pathologic mechanism(s).98 This implies that AD, PD, and ALS are essentially the same disease with a slight variation on a theme. The theme is pesticide poisoning, and there is a synergistic99 effect of heavy metals (think aluminum and mercury)…Assuming one does not have Lyme or Parkinsonism from a toxic exposure, such as carbon monoxide, it is worth a trial of 4-PAS or 5-ASA, which will selectively chelate manganese (Mn) from the human body. Mn is an essential trace element but can be absorbed or ingested in toxic forms and in excess. Exposure can be from gasoline to well water. If the 4-PAS or 5-ASA changes symptoms, this is about Mn toxicity issues.119 Glutathione is not a specific detoxification agent for just Mn, but a large dose will help remove some of it. Mesalazine, also known as mesalamine, is 5-aminosalicylic acid (5-ASA), and like 4-PAS is considered by conventional medicine to be anti-inflammatory because it helps treat inflammatory bowel disease. It is the active part of the antibiotic sulfasalazine, which is used to treat Crohn's disease.for more, see https://robertyoho.substack.com/p/244-wholistic-treatments-for-parkinsons#detailsSupport the show

Zoe Lalji is a junior at UT Austin studying neuroscience with a minor in entrepreneurship on a pre-med track, and she is working to make virtual reality accessible to ALS patients. In this episode, she discusses what it was like when her dad was diagnosed with ALS and how that changed the trajectory of her career, her work with advancing virtual reality technology to better support patients' lives, and how hardship has developed an essential self-awareness.   Guest links: https://www.linkedin.com/in/zoe-lalji/ Charity supported: ALS Heroes Interested in being a guest on the show or have feedback to share? Email us at podcast@velentium.com.  PRODUCTION CREDITS Host: Lindsey Dinneen Editor: Tim Oliphant Producer: Velentium   SHOW TRANSCRIPT Episode 010 - Zoe Lalji Lindsey Dinneen: Hi, I'm Lindsey with Velentium and I'm talking with MedTech industry leaders on how they change lives for a better world. Diane Bouis: The inventions and technologies are fascinating and so are the people who work with them. Frank Jaskulke: There was a period of time where I realized, fundamentally, my job was to go hang out with really smart people that are saving lives and then do work that would help them save more lives. Diane Bouis: I got into the business to save lives and it is incredibly motivating to work with people who are in that same business, saving or improving lives. Duane Mancini: What better industry than where I get to wake up every day and just save people's lives. Lindsey Dinneen: These are extraordinary people doing extraordinary work, and this is The Leading Difference. Hello and welcome to The Leading Difference. I'm your host Lindsey, and I am so excited to introduce you to my guest today, Zoe Lalji. Zoe is a junior at UT Austin studying neuroscience with a minor in entrepreneurship on a pre-med track. Her passion for neuroscience began when her father was diagnosed with a Amyotrophic Lateral Sclerosis (ALS) in 2017. And since then, she has been constantly searching for ways to improve his quality of life and expand his avenues of connection with the world around him. As part of this work, she is working to make virtual reality accessible to ALS patients and other highly disabled populations as a way to provide them with autonomy in the form of novel experiences and immersive activities that they're unable to engage in physically. Zoe, oh my gosh, thank you so very much for joining us. I am just so very delighted that you're here and I just can't wait to hear more about your story and your background. But first, thank you just so much for being here. Zoe Lalji: Aw. Thank you, Lindsey. Thank you so much for inviting me. It's awesome to be a part of this great podcast you have. Lindsey Dinneen: Awesome. Well, I was just wondering if you wouldn't mind starting by just telling us a little bit about yourself and your background and what led you to what you're doing now. Zoe Lalji: Sure. So, right now I'm a junior at UT Austin and I'm studying neuroscience on a pre-med track and minoring in entrepreneurship. And as far as what kind of got me to where I'm at and-- I've been passionate about medicine for as long as I can remember. Both of my parents are in medicine. My dad was a dentist and my mom studied as a gynecologist and transferred into functional medicine. And they both had their own practices, so I've had that business background as well. But that all shifted, I would say, when my dad was diagnosed with ALS in 2017. And from there it was a pause button if you could say on on my entire scheme of my life, my plans. You know, I think with pre-meds there's a track that is a starting point and you have a series of events that are lined out for you until you reach medical school and get that MD. And that kind of stopped me in my tracks and made me reassess what was truly important because I had to spend a lot of time caring for my dad, caring for my family, and it definitely shifts your priorities and makes you reassess your life. And although, everything was still of in line with my values growing up, which was, I've always wanted to help people and that's what drew me to medicine. That's what I had really admired about my parents is the impact they had made on others' lives that were struggling, that had health conditions and needed guidance in that area of their lives. And I think watching my dad undergo one of those health conditions and just doing everything in my power to make it better for him in any way that I can. It just truly strengthened that core value for me. And I think when you're in pre-med, there's kind of a tendency to get tunnel vision. And, kind of that check mark mentality where you go, "Do I have the grades? Do I have the volunteer hours, the extracurriculars," all that stuff. And I think, you lose sight of the why of medicine, until even after residency when you're actually in the field where you actually meet the patients and you actually you know, talk to the people that are struggling and realize how important it is. And until then, it's more about, memorizing facts and figuring out how the body works without really putting it into the context of the bigger picture. So I think studying medicine alongside actually understanding what it's like to be on the other side, on the patient perspective, was a real driver for me. I guess the turning point for me for where I really realized that making an impact for medical problems is where my heart really lies. Lindsey Dinneen: Yeah, that is such a powerful story, so thank you for sharing that. I was wondering if you would be willing to share a little bit more about ALS and how that affects people's lives. I know it's a very difficult disease, but just from your perspective, especially having experienced it and trying to help someone who is dealing with it-- I would just love to hear a little bit more about it. Zoe Lalji: Yeah, absolutely. So ALS is a neurodegenerative disease. It impacts the motor neurons in the body, which effectively causes people to lose their ability to walk, talk, move any part of their body and eventually breathe on their own. And it's a interesting disease in that there's not much known about the pathophysiology of it, in that like they don't know what causes it. They don't know how to even approach treatment. Only 10% of ALS cases have been found to be connected to a gene. And even then they haven't really found a way to reverse any of that. So it's a completely uncured disease, the treatment is very limited, in that there's maybe a few months of life expectancy increased by the treatment, but in contrast you get a lot of side effects from it, which effectively makes you pretty much zombified. You know, it's a lot of fatigue, a lot of nausea, and a lot of patients just opt not to do it because the quality of life is really reduced from just being on those treatments. And so it's just a hopeless disease. And when you're given that diagnosis and told that it's always fatal and there's nothing that really you can do, you just feel completely helpless. And then as you lose your agency over your body, your ability to do things on your own, that helplessness sort of grows and consumes you. It's a very difficult disease to be diagnosed with on the patient and the family. Lindsey Dinneen: Of course. Yeah. Well, and I know part of your work, something that you are doing right now is working to make virtual reality accessible to ALS patients. And I love this idea, and I would love if you would be willing to share more about this and what brought that idea about and where is it taking you. Zoe Lalji: Yeah, of course. I love talking about it. This idea came from just my desire and my constant searching for things to do with my dad or things to bring him happiness in his life, or greater quality of life. And it came about from actually an internship I had during my gap year, which I took before college. And I was at a startup accelerator and there was a XR lab in the accelerator where they had virtual reality headsets, and I had talked to the head of the lab and he let me use one of his headsets and I ended up using Google Earth on the headsets. And I don't know if you've ever used virtual reality, but for whoever has used it, it's very life like, like you actually feel like you're there. You feel like you're walking the streets of Rome or you're in, you're in Paris, or so many different places that you can just click a button and just be fully immersed there. And that's just Google Earth. There's so many other immersive scenarios that you can dive into in virtual reality. And with the immersion of the Metaverse and so many different concepts of the growing interest in virtual reality as a way to have a life outside of the physical life. And just from seeing that Google Earth scenario, immediately I thought, "Wow, this would be incredible for my dad." Because for patients that have all of these life support machines, when they lose their breathing, you have to get a surgery and you have to be basically connected to a machine that controls your breathing. And obviously with that, you can't travel, you can't get on a plane. And for many of these patients, like my dad, you have all these hopes of where you would like to travel one day, things you would like to do one day, and life just happens and you don't end up doing it. But you always think there's time. You always think, " Maybe when I retire, I'll go and travel the world." The common notion that people say. When something like this happens and puts your life in pause where you realize you're never gonna be able to travel again, or you're never gonna be able to skydive or bungee jump or do those bucket list things that you said that you would one day do. And like, even further than that, it's more the things that you used to do every day that sort of defined you, that sort of made you feel like-- for example, my dad would, for as long as I can remember, probably my earliest memory of him is him waking up every morning and going for a run. And he never missed a day. And it was so important to him, like being who he is and his day working out the way he wanted it to, that he had that run, he had to start his day off feeling like himself. And I feel like we all have those hobbies and habits that really all together define who we are. And when you get a disease, not only is it like you're losing all of those things all at once, you start to define yourself as your disease then, because there's nothing else really left. I think for me, virtual reality meant giving those back this semblance of who they once were that they've lost. I think we're all the sum of what we do every day and our dreams and hopes for the future. And when those are taken away, it's who are we really? And that's not even considering the communication that patients lose. So you can't even really express yourself either. So with that, it's like there's this huge disconnect with their identity and I, I just see VR as a way for these patients to enter the world where they don't have to be defined as their disability, where they can do everything that anyone else can in virtual reality. And the problem lies with the modes of interaction with the devices where VR right now has remote controls that you need to use to interact with the environment, and you have to walk around to see the full environment, which for all quadriplegics, there's no really way to do that. So I'm trying to make that aspect accessible for that population so that they can have access to those virtual life-like immersive experiences that can tie them to the things that they used to love or would love to do one day. Lindsey Dinneen: Yeah. So essentially taking some of the existing tech, but putting it into a new method of delivery, I suppose? So that folks who can't, like you said, walk or that can't necessarily interact through a series of controllers or something like that, would be able to still experience those wonderful, immersive things. Is that... Zoe Lalji: Yeah. Yeah, exactly. Lindsey Dinneen: Ok. Wow. Yeah. Oh my goodness. Okay. This is so exciting, just to hear all about this. I know that you are still pursuing medicine and then now you're also pursuing this sort of tech side of things. I understand the background of you coming into it and why, but how have you found these interactions? Have they played out easily? Has it been an odd transition, or how has that all worked out? Zoe Lalji: Yeah, as you can imagine, it's like I have two sort of big things that I love and I'm passionate about and they both take a lot of time and effort and energy. And to say the least, it has been difficult to prioritize one or the other and find the time in the day for both. What I love about medicine is that the hope that we can bring to the patient. I love the innovation of it. I love coming up with solutions that aren't out there, that for the patients like my dad that don't see hope in existing medicine. I wanna be the hope for those patients. And that's, that's how I feel right now. I, I know I will always love every aspect of medicine, but that's what really drives me is that notion of helping those people that are feeling the medicine has failed them, and providing them with unconventional solutions that maybe they didn't think to look for or didn't think that there was one, you know? I think that until there's a cure for some of these diseases, technology can bridge that gap of function and bring back what people have lost. And I've seen it, I've worked with Paradromics as a BCI company in Austin and that was my first exposure since developing my startup into the, the medical technology world. And they're just such a amazing team and they have such a noble cause that they're fighting for and they just wanna help people like my dad. And to be surrounded by people that want to do that and the technology and seeing how impactful it has the potential to be. It really inspired me, especially coming from such a hopeless diagnosis that we had, it really gave my family hope. It gave me hope, and that's the feeling I wanna give to other people. And so my plan right now is to finish out my pre-med prerequisites in college and take a gap year or two to really work on my startup, really work on things like put myself in different environments in the medical technology world, get more experience and really understand my passion and what I can offer to the field. And from there I'll really decide if an MD is the right path for me or if I want to go a different route to get a different degree, you know, and still work within medicine, but not maybe bedside and not maybe in a hospital and not maybe with direct patient care. So yeah, I think that's the route I'm thinking right now? Yeah that's the plan. Lindsey Dinneen: Yeah. That's a great plan. And I love, I love your willingness and your openness to explore and continue to evolve, perhaps, over time in terms of, when you go into a new path and you've had this set of expectations for yourself for a while, that this is where you were going to head. And then things change and I just think it's quite remarkable when someone like you who is obviously very talented, smart, multi-passionate, is able to pivot and say, " I love this aspect, but I also love this aspect and maybe I can do both in a really creative way." I think that's fantastic. Zoe Lalji: Yeah, I mean, it was such a difficult thing for me since I had wanted to do medicine my whole life. It was something that was so ingrained in who I thought I was. Everyone asks you when you meet them, like "What do you wanna do with your life? What are you majoring in? What's your path?" And always it's pre-med, ever since I was a kid, I'd say pre-med, and it's strange to change that. And I think what really helped me get there is my life has been so turbulent and I've had to really get used to things not being how I planned, you know? And like that with my dad's diagnosis, throwing us into a spiral. And then after that actually, the gap year itself was another event that I had not planned for. I had decided to take one because my dad really needed me, and I found in my value scope that really came first before anything else. And then it became a serendipitous decision because in December, after I had taken my gap year, my mom was diagnosed with breast cancer. And luckily she's cancer free now, but we had to go through chemo, radiation, surgery and I could not have dealt with that at college. I had to be home, I had to be with her. And somebody had to take care of my dad. Somebody had to help her keep everything together and keep herself together. And I think, that was probably one of my biggest teachers is that, things are gonna happen. You can't avoid change, and I think that was really difficult to realize that maybe my plan wasn't the right plan for me, and maybe I need to take a second and let myself sit in the ambiguous unknown, which is really uncomfortable, but sometimes it's necessary in order to figure out where you really belong. But yeah it's definitely not easy. I definitely have not figured everything out. It's definitely some days I'm like, I just want to go back to the known, it's so much easier. But yeah, I think it's just getting used to the unknown and getting used to change. Lindsey Dinneen: Yeah. Yeah. And kudos to you for that viewpoint. And I'm sure, I'm sure some days are easier than others. I certainly understand that. But seriously, kudos to you for being willing to adapt to changing circumstances that you didn't plan for and you wouldn't have wished for, but this is really amazing to me as to how you've taken something that is so incredibly difficult and challenging, but you've really embraced the challenge-- and maybe that was a long time in coming-- but you've embraced that challenge and then you're not just helping your own family, which is incredibly important, but you're doing work that's gonna help so many people. And I think that is just amazing. Thank you for doing what you're doing. Zoe Lalji: Absolutely. Like you said, it definitely was a long time of really a lot of self-awareness, a lot of self-work, to get to a place where I was ready to embrace it, like you said, like it's something that has been difficult, has been so trying on our family, so trying on my dad. And a lot of days I am like, why did this happen? And I feel a lot of grief and a lot of sadness and unwillingness to embrace it. But for the most part, I've reached a point where I've realized that this is something that we've come a long way from, and we try to make the best out of the situation and make every day as bright as we can, given everything. And that's all we really can do. And I think watching my dad overcome it himself has been just what has given me the strength I need to get out of that sort of pity, out of that grief of like, why me? Why has this happened? And anger because when you think about what ALS patients go through, it's like you just can't even imagine what it could be like to be in that position. And to watch my dad really take that in stride and be this ferocious warrior through it and keep fighting no matter what life throws at him. He's almost at six years since his diagnosis and he's still fighting and he's still finding a reason to smile every day. And when I think about that it reminds me that it's okay. If he can fight like he's been fighting, then we all have that strength in us and that's, I think, what inspires me to want to help people like him, to want to bring more light into others' lives that are going through what we've gone through. And I think it's our duty really. I think I've gotten a very unique experience to watch somebody rise from the ashes and learn from that and I think that hardship, it sucks, and I'm not gonna say it doesn't at all like it, it does suck. All of it sucks, but it's an opportunity to learn. It's an opportunity to grow and it's an opportunity to become the best version of yourself through it. And there's moments when you don't want to learn , you know, you just, "I'm done with the lessons," like "I've had enough!" I think at the end of the day, it's like everything that I am and everything that I've learned it's valuable, regardless of what I have to go through to get me here. It's who I am. And so I think the best thing I can do with that is use it as a way to empathize with others in a way to really understand what's needed and how to help people that go through similar things that I've seen with my dad. Lindsey Dinneen: Yeah. Yeah. That's absolutely beautiful. Well, I'm wondering is there a particular moment or perhaps series of moments that stands out to you because it clearly confirmed that this was the right career path for you, even though it's been a bit of a meandering one, a pivoting one. Is there any particular moment where you thought, "Okay, this is why I'm here." Zoe Lalji: Like you said, it's a lot of moments. I mean, I would say the first moment was definitely when my dad was diagnosed. But even then I didn't really make that shift of " I'm definitely gonna do this for the rest of my life." It was more of a shock where I realized this is something I really care about. But I think really working on my startup has been so empowering. And then also my internship at Paradromics. I think the main moment that recently has made me realize that kind of clarify what exactly about medicine really drives me is I was invited to speak at a brain computer interface conference at the Chamber of Commerce. And through that I met so many key players in the the ecosystem. And I spoke to a lot of them about what I was passionate about, what I was doing, my story. And it was remarkable to me that so many people really cared and it was so obvious that everyone genuinely cared about the patient and about helping that person. It wasn't about the product, it wasn't about the business. It was about how can we help people the best way that we can and how can we use the potential of this technology to really help people's lives. And I think that energy and being in that space of like people just wanting to help, that was just so new for me because I think when something happens like that, you feel so incredibly alone and nobody could ever really help you, and it's like there's no hope. And people can try to support you and they can try to take care of you, but there's no way that they can actually help. And then even from the medicine side, there really wasn't anything there. And to enter into a room where so many people were making things actively that could help, for me as a daughter of somebody that was going through it, it wasn't so impactful and it made me think what about for others that are like me or for others that are like my dad to be exposed to this world of increasing potential and technology. And I was like, this is where I wanna be. This is home. Lindsey Dinneen: Wow. Yeah. That is a very powerful story. Thank you for sharing that. I have been personally so inspired by people in the medtech industry and healthcare because, you know, you start talking to them and it's easy to see how much they care. It's like you said, it's not just about the product, it's not just about the business, it's not about making money, although everyone needs to to make a living but it's about truly helping people, and I think that's just one of the most inspiring things that I have personally gotten to witness by meeting truly remarkable people through this field. That makes sense to me that, that was a moment that stood out for you. Well, that's amazing. Well, I'm curious, so you're in a really interesting new phase. Yeah. And I, I'm curious as you continue to develop your startup and whatnot, how would you define leadership? Or what does leadership mean to you? Zoe Lalji: I think for me, and from my experience with it, leadership is really about empathy and understanding your team. And the analogy I would use is like a wolf pack. The leader of the wolf pack is always walking behind the pack and making sure nobody gets lost and making sure everybody has purpose and a destination. And I think that as a leader, it's your responsibility to make sure that the team is whole, in a way, where everybody on the team-- you understand them enough to know their strengths and to know their tendencies and set them up to succeed and set them up to benefit the full team and have everybody on the team feel like their strengths are building the team into the best version of itself. And I think having that ability to really understand people really qualifies someone as a great leader. And I, I would liken a leader to a mentor in a way, because it's not about you, if you're leading a team, your success is the team's success, right? And your goal is to inspire success in each of the individual people on the team so that the team can be greater than the sum of its parts. Because everyone's strengths play in a way that they add to each other and compliment each other. And I think from what I've found is that when people realize that you truly understand them and you see what really makes them unique, they're more willing to devote those strengths to whatever cause you're going for. And they're more attentive to the goals you place for the team, the end goal. And I think another thing that a leader really has to do is understand the why of the team and really show that or really demonstrate that to the team and align them under the same why. Because I think what makes a team really unique is their ability to align themselves under that goal and all fight for that goal together. I think those are two things that I find are really important in a leader. Lindsey Dinneen: Yeah, absolutely. Agreed. Yeah. So pivoting a little bit, just for some fun. Imagine someone were to offer you a million dollars to teach a masterclass on anything you want. It can be in your industry or something you're working on now, but doesn't necessarily have to be, what would you choose to teach and why? Zoe Lalji: Wow. That is a fun question. Wow. Okay. I think I would probably want to teach a class on self-awareness through hardship. I think that is one of the biggest things that I have struggled with especially when I think in my gap year was the biggest moment where I realized, I am really defining myself as a caregiver. I'm defining myself as someone that cares for others because I did that every day. And it was so difficult to have my own identity, to have my own sense of self, and I think that really finding that balance of what do I need to be the best version of myself and to do the best for others because of that. I think that journey for me of really finding what's important to me, reprioritizing, because I think moments like these shift your priorities so much. They shift your view of the world. They shift who you are. And to catch up with that is there's so much change going on in your life to keep a pulse on you and who you are, what you stand for, is so incredibly difficult. And I think if you're not careful and you're not placing importance on that, you become misaligned and you don't live in your true values. You don't live within your true values because you don't have that alignment within yourself. And I think, once you've gone through a phase where you've completely lost sight of that and it's a phenomena with caregivers that we tend to forget about ourselves completely. And we place focus on others, on the people we're caring for. And I think in my gap year with both of my parents needing me to be there for them, it made me feel like this is more important, right? Because before the diagnosis with my dad, my highest priority was always family. And caring for others and giving back was such a huge thing that had been instilled in me, and it's still a huge priority for me. But I never had to take care of myself. I never had to place importance on that because there was never a point where I was gasping for air and gasping for care. And I think it also just felt like I didn't know who I was anymore, and that's such a terrible place to be in. And that's why I can say that for, for patients that undergo this, it's that to a totally different extent, and that goes back to my VR project. But I've done so much, coming into college and really getting the space to put myself in different scenarios and see who I am.  I think that sitting with myself and taking that time and doing that work has really allowed me to be there better for my parents, be there better for my family, because I'm just more aligned. I'm more me. And being around my dad when I'm not even me is not helping him. He wants to spend time with me. I think when you neglect yourself, it's hard to be you, you know, it's hard to explain, but I think just having that alignment through something so pivotal in your life, something so earth shattering that happens to you, that kind of shifts who you are. And keeping track of that shift and keeping yourself in your care and treating yourself as a child, because you are. You have to nurture your inner child and really take care of that child and not think that child is perfect because they're not. And the thing about this particular class would be that I haven't figured it out. But I have done a lot of work and I would want to help people that are trying to navigate that because I feel like there's been a lot of trial and error and if I can help people in any way with my experience with it and what's worked for me, and how I went about figuring out what works for me, I think finding that balance within such a all-consuming situation and hardship, that I would wanna help people through that. That's been monumental for me in realizing that myself was important, in defining myself and being aware of myself and who I was. And so yeah, I think realizing that was important through all of this hardship. I think that's one of the biggest learning moments for me, and I'd really wanna share that. Lindsey Dinneen: Yeah. Yeah, absolutely. And like you said, there are so many people who are going through similar things that could really benefit from that. So that would be an amazing masterclass. So I'll look forward to that whenever that comes up. What is one thing you wish to be remembered for after you leave this world? Zoe Lalji: Honestly, I feel like my impact will be in the lives that I've impacted, and if I can be remembered as a friend, as an advocate, and as a mentor for those people, I would be fulfilled. I feel like I would just want to at least help one life that needs that guidance, you know, that feels so alone and feels so hopeless, to bring that small amount of hope, even if nothing at all. And I think where my fulfillment comes is that I want to help people like my dad, people like me, people that have been struggling, that can't find what way is up, which way is the light, either guide them or provide them with some semblance of hope. Or just be a friend, or just be support. Because coming from someone that's been there, coming from someone that can empathize and make them feel like, "Hey, you're not alone. It might feel lonely and it might suck, but you're not alone." Lindsey Dinneen: Yeah. Yes. Absolutely. That is very powerful. Final question, what is one thing that makes you smile every time you see or think about it? Zoe Lalji: Well, I think that one is easy because it's my dad. He's my inspiration. He has so much light within him that only comes from overcoming something like this. And his energy is just so incredible, and he is the reason I keep doing what I do. And I think also, the memories I have of him, the memories of him as my father when I was a kid and things that he used to do with me and things that just really showed that he loved me so much. And those memories that are just so sacred to me and every time I think about it, it's bittersweet, but it always makes me happy to remember what he means to me. Lindsey Dinneen: Yeah, absolutely. Well, Zoe, oh my gosh, you are so very inspirational. I would not wish the path that you have taken on you in the way that it has happened, but I just admire you so much for taking a very hard path, but making so much good come from it and embracing the light and embracing choosing to help others see that light and see hope in a difficult time. Gosh, I cannot wait to continue following your work and seeing what you do because I know you're gonna be impacting a lot of lives. Oh my gosh. Zoe Lalji: Thank you. Yeah, and I really loved being on your podcast. I loved talking to you. This form is amazing and I can't wait to see what other amazing speakers you get on here. Lindsey Dinneen: Awesome. Well, thank you, and we are so honored to be making a donation on your behalf as a thank you for your time today to your family's organization, which is ALS Heroes. This organization honors the heroes amongst us who have stared devastation in the face, only to say, "you do not define me." The organization hopes to guide those heroes in navigating their resources and provide them with hope in the midst of a seemingly hopeless disease. And I'm so excited to continue to learn more about the organization and how we can get involved. So thank you for bringing our attention to it, and thank you again for being here. We wish you continued success as you work to change lives for a better world. Zoe Lalji: Thank you so much, Lindsey. It's been a pleasure. Lindsey Dinneen: Absolutely, and thank you also to our listeners for tuning in. If you're feeling as inspired as I am right now, I would love it if you would share this episode with a colleague or two, continue to pass along the word, and we will catch you next time.  The Leading Difference podcast is brought to you by Velentium. Velentium is a contract design and manufacturing firm specializing in the development, production and post-market support of diagnostic and therapeutic active medical devices, including implantables and wearables for neuromodulation and other class three indications. Velentium's core competencies include electrical design, mechanical design, embedded software, mobile apps, contract manufacturing, embedded cybersecurity, OT cybersecurity, systems engineering, human factors and usability, and automated test systems. Velentium works with clients worldwide from startups seeking seed funding to established Fortune 100 companies. Visit velentium.com to explore your next step in medical device development.

In this deeply personal documentary EAT YOUR CATFISH we meet the matriarch of the Arjomand family, Kathryn, now dependent on round-the-clock care, due to a harrowing diagnosis. She clings to a mordant wit while yearning to witness her daughter's wedding. Co-directors and producers Adam Isenberg, Senem Tüzen and Noah Amir Arjomand — who is Kathryn's son — deliver a brutally frank and darkly humorous portrait of a family teetering on the brink, grappling with the daily demands of disability and in-home caregiving. With her daughter Minou's wedding day approaching, Kathryn is determined to live to see her child get married. Years with Amyotrophic Lateral Sclerosis (ALS) aka Lou Gehrig's Disease, have left Kathryn paralyzed and needing 24-hour care. She relies on an eye-tracking, speech-generating computer to impart her wishes, but it can be an uphill struggle to be ‘heard'. With her mind intact and having opted for mechanical breathing, she could live like this indefinitely. EAT YOUR CATFISH is draws on 930 hours of footage – all filmed without any crew present from a fixed camera and narrated by Kathryn. The result is a profoundly intimate, layered and wryly funny portrait of a family at its breaking point. Co-directors Noah Amir Arjomand & Adam Isenberg (Senem Tüzen) joins us to talk about the ways this film project came about, why they adopted the POV approach to telling the story and how seeing the world from the point-of-view Kathryn could positively impact other family's dealing with a loved one in a comparable medical condition. For more go to: eatyourcatfish.com For more on the POV screening: pbs.org/pov/eatyourcatfish

Six years ago when former Obama staffer Brian Wallach was diagnosed with Amyotrophic Lateral Sclerosis - ALS - a rare neurological disease that kills most people who contract it within a few years, he and his wife Sandra Abrevaya quickly got to work. They launched a non-profit advocacy group I am ALS and a battle to try and fight for increased funding and research that they hoped would lead to a cure for the disease.Since then Wallach and Abrevaya have changed the face of medical advocacy in the country, helping secure legislation that President Biden signed in 2021 that funds $100 million worth of ALS initiatives each year. NPR's Juana Summers spent time with Wallach and Abrevaya to hear about their fight for a cure for ALS.In participating regions, you'll also hear a local news segment to help you make sense of what's going on in your community.Email us at considerthis@npr.org.

What if you could help revolutionize how we care for people with Amyotrophic Lateral Sclerosis (ALS)? Mohammad Sahal, with his unique blend of computer science and neuroscience expertise, is doing just that! Join us for the third episode of the BCI Award Neurocareers podcast series as we take a deep dive to learn how the non-invasive, low-cost, portable neuroergonomic BCI system is transforming the way we care for ALS patients. Discover how custom augmented reality displays are helping patients improve their quality of life from the comfort of their own homes and how this technology is breaking down barriers and revolutionizing healthcare! Join us as we continue exploring the fascinating world of neurotech and focus on the project "A Neuroergonomic BCI with Custom Augmented Reality Display Targeting Continuous At-home Use for People Living with ALS," developed by Sahal and his team, which was nominated for the International Annual BCI Award 2021. Sahal also shares his advice for early career development in the neurotech field and suggests how to submit a successful BCI Award project. This podcast is brought to you through the partnership between Dr. Christoph Guger at g.tec medical engineering GmbH and Neurocareers podcast host Milena Korostenskaja, PhD at The Institute of Neuroapproaches. So why wait? Listen now and be a part of the neurotech revolution that is transforming lives! Join the revolution by submitting your project for BCI award: https://www.bci-award.com/Home About the Podcast Guest: Mohammad Sahal is a tech wizard with a heart for healthcare! With a degree in computer science and minors in neuroscience and mathematics, Mohammad is a triple threat when it comes to developing innovative solutions that merge the worlds of technology and healthcare. He works at Microsoft on the Azure Networking team, focusing on the Web Access Firewall and Content Delivery Network services. But Mohammad's true passion lies in using his expertise to positively impact people's lives. During his time at Drexel University, he led efforts to develop Brain-Computer Interface (BCI) systems for individuals with ALS and other motor neuron diseases (MNDs) - talk about using your skills for good! The project aimed to create a non-invasive, low-cost, portable system that could be used in the comfort of the patients' homes. Mohammad's innovative project has gained recognition in the neurotech community, with his team's project even being nominated for the International Annual BCI Award 2021. With a passion for innovation and a heart for helping others, Mohammad quickly becomes a rising star in the neurotech field. So if you're looking for a tech wizard with a heart of gold, look no further than Mohammad Sahal! Connect with Mohammad Sahal on LinkedIn: https://www.linkedin.com/in/mohammad-sahal/ About the Podcast Host: The Neurocareers podcast is brought to you by The Institute of Neuroapproaches (https://www.neuroapproaches.org/) and its founder, Milena Korostenskaja, Ph.D. (Dr. K), a neuroscience educator, research consultant, and career coach for students and recent graduates in neuroscience and neurotechnologies. As a professional coach with a background in the field, Dr. K understands the unique challenges and opportunities facing students in this field and can provide personalized coaching and support to help you succeed. Here's what you'll get with one-on-one coaching sessions from Dr. K: Identification and pursuit of career goals Guidance on job search strategies, resume and cover letter development, and interview preparation Access to a network of professionals in the field of neuroscience and neurotechnologies Ongoing support and guidance to help you stay on track and achieve your goals You can always schedule a free neurocareer consultation/coaching session with Dr. K at https://neuroapproaches.as.me/free-neurocareer-consultation Subscribe to our Nerocareers Newsletter to stay on top of all our cool neurocareers news at updates https://www.neuroapproaches.org/neurocareers-news    

Laynie Dratch of Penn Medicine comes onto the podcast to answer all of our burning questions about working with a genetic counselor. We loved chatting with her so much that we may need to follow up with a part 2! Let us know what other questions you have for Laynie on our episode art on instagram @remembermepodcast. A list of resources mentioned in this episode are all linked here on our blog. Laynie Dratch, ScM, CGC is a genetic counselor in adult neurology at the University of Pennsylvania in Philadelphia, PA, specializing in Frontotemporal Degeneration (FTD) spectrum disorders.  She helps families with adult-onset conditions such as FTD, Amyotrophic Lateral Sclerosis (ALS), Alzheimer's Disease (AD), and others, navigate genetic testing options and cope with their diagnoses through research and clinical encounters. Her research interests include the lived experiences of individuals with or at risk of developing FTD, issues in predictive genetic testing, and genetic counseling access and service delivery. She is a co-founder of the annual Penn Familial FTD/ALS Conference, as well as the co-founder and chair of the ALS/FTD Working Group within the National Society of Genetic Counselors. Laynie graduated summa cum laude from Colgate University with a BA in neuroscience and a minor in psychology. She completed her master's in genetic counseling at the Johns Hopkins University and the National Institutes of Health. --- Thank you to our sponsor of this episode and Season 7, ⁠⁠LearnFTD⁠⁠. LearnFTD is working to raise awareness of gene mutations in FTD and the importance of genetic testing. Visit ⁠⁠LearnFTD.com⁠⁠ for information and resources on FTD, genetics, and a video providing an overview of genetic testing and counseling. You can also follow LearnFTD on ⁠⁠Facebook⁠⁠ and ⁠⁠Instagram⁠⁠ @LearnFTD. --- ⁠⁠Remember Me⁠⁠ is a podcast created by two moms who became fast friends on Instagram while caregiving for their parents. It features stories of Frontotemporal Dementia - FTD - with a focus on remembering individuals for who they were before the disease. The stories shared are raw, real, and so full of love. We hope it inspires you to "accept the good." "Always, always, accept the good." --- Support this podcast: https://podcasters.spotify.com/pod/show/rememberme/support

Motor Neuron Deficits: Lesions leading to lost function! Join Hand to Shoulder with Cassie and Shelly as we dissemble motor neurons and variations of symptoms, which in turn, lead to ALS. This very energetic podcast with Cynthia Ivy out of Phoenix, AZ, will open your mind to neurological deficits and the role of a hand therapist with someone who presents with hand or upper limb weakness. We hope you gather several takeaways from this complex topic. Cindy Ivy OTD, M.Ed., CHT began working as adjunct faculty at NAU, Phoenix Biomedical Campus in 2014 and joined the faculty in August of 2015 as Associate Clinical Professor and Residency coordinator. She is studying the effects of carpometacarpal stabilization exercises on pain from osteoarthritis of the first carpometacarpal joint. Her research interests also include studying functional outcomes of the use of finger orthoses versus injection for stenosing tenosynovitis (trigger finger) and studying quality of life and positive effects on function and independence in persons with Amyotrophic Lateral Sclerosis (ALS). In addition to ALS, She is also studying interventions to improve independence in people with Parkinson's Disease. Dr. Ivy carries a bachelor's degree in occupational therapy from the University of Wisconsin, Madison and a Master's of Education in Counseling Psychology from Northern Arizona University. Her post professional clinical doctorate in occupational therapy, Hand therapy emphasis is from Rocky Mountain University of Health Professions. Cindy Ivy has a passion for teaching and has taught in many capacities over the past 30 years while working as a hand therapist and occupational therapist Susan M Smith, C. C. (2015). Upper Extremity orthoses use in amyotrophic lateral sclerosis/motor neuron disease: A systematic review. International Journal of Physical Medicine and Rehabilitation, 03(02). https://doi.org/10.4172/2329-9096.1000264 Ivy, C. C., Smith, S. M., & Materi, M. M. (2014). Upper Extremity orthoses use in amyotrophic lateral sclerosis/motor neuron disease: Three case reports. HAND, 9(4), 543–550. https://doi.org/10.1007/s11552-014-9626-x

Partner Chicago Regional Office Veteran Benefits Administration Panelists:Monica Arango  - Chicago Regional Office Veteran Benefits Administration Subject Matter Expert and POW Coordinator Exam Liason.Molly Sikora  - Chicago Regional Office Veteran Benefits Administration Management Analyst and Director's Staff.Roberto  Salazar  - Chicago Regional Office Veteran Benefits Administration Records and Information Management Specialist, Support Services Division, and US Marine Corps Iraq Combat Veteran 

Fran Finney, wife of bitcoin legend Hal Finney joins us to talk about Hal's Life, her work with Asher Garfinkel in fighting ALS with the "Running Bitcoin Challenge". Fran and Asher go in-depth on what Amyotrophic Lateral Sclerosis (ALS), also known as Lou Gehrig's Disease is, how bitcoin has changed their lives and more. We also cover the bitcoin news at the beginning of the show and talk about the mining incentives with a fixed supply unit such as Bitcoin. Guest Information: Fran Finney: https://twitter.com/franfinney Asher Garfinkel: https://twitter.com/alsagoldenwest Connect with Alex: Alex Stanczyk Twitter: https://twitter.com/alexstanczyk Sign up for Swan Private today: https://www.swanbitcoin.com/private/ "Buy, Learn and Earn" with the Swan Bitcoin Mobile App: https://www.swanbitcoin.com/app/ Hello and welcome to The Café Bitcoin Podcast brought to you by Swan Bitcoin, the best way to buy and learn about Bitcoin. We're excited to announce we are bringing the The Café Bitcoin conversation from Twitter Spaces to you on this show, The Café Bitcoin Podcast, Monday - Friday every week. Join us as we speak to guest like Max Keiser, Lyn Alden, Tomer Strolight, Cory Klippsten and many others from the bitcoin space. Also, be sure to hit that subscribe button to make sure you get the notifications when we launch an episode. Join us Monday - Friday 7pst/10est every Morning and become apart of the conversation! Thank you again and we look forward to giving you the best bitcoin content daily here on The Café Bitcoin Podcast. Swan Bitcoin is the best way to accumulate Bitcoin with automatic recurring buys and instant buys from $10 to $10 million. Get started in just 5 minutes. Your first $10 purchase is on us: https://swanbitcoin.com/yt Connect with Swan on social media: Twitter: https://twitter.com/SwanBitcoin

Join us for a special episode on the innovative efforts to help those living with Amyotrophic Lateral Sclerosis (ALS). Israeli neurotech scientists and educators have organized a national program using brain-computer interfaces (BCIs) to improve the lives of those with ALS. In this educational program, students learn about BCIs and use their knowledge to create personalized devices for patients to address their individual needs. Tune in to learn more about this unique program from its leader Asaf Harel and appreciate the hope it brings to those living with ALS! About the podcast guest: Asaf Harel focuses on designing and developing brain-computer interfaces for human sensory and motor systems, data analysis, signal processing, machine learning, and multi-site experimental coordination. Asaf believes that "in the near future, our interactions with the digital world will be mediated by our attention and intention, augmenting current touch, gesture, and speech inputs." Asaf is the co-founder and leader of BrainstormIL, an organization dedicated to establishing Israel as a neurotech leader. With a community of over 3000 members across eight chapters at top academic institutions in Israel, BrainstormIL hosts national events, competitions, courses, conferences, and connections to stakeholders in the Israeli neurotech ecosystem. Useful links: www.brainstormil.com - Israel's Neurotechnology Community (Non-Profit Organization) www.neurotechx.com - A wonderful global community advancing and connecting the neurotech community www.brainstormil.com/bci-4-als - The site for the BCI4ALS program www.linkedin.com/in/asaf-harel/ - Asaf's LinkedIn page   About the podcast host: The Neurocareers podcast is brought to you by The Institute of Neuroapproaches ( https://www.neuroapproaches.org/ ) and its founder - Milena Korostenskaja, Ph.D. (Dr. K) - a neuroscience educator, neuroscience research consultant, and career coach for students and recent graduates in neuroscience and neurotechnologies. As a professional coach with a background in the field, Dr. K understands the unique challenges and opportunities facing students in this field. Whether you're looking to apply for jobs, build your professional network, or develop your research skills, Dr. K can provide personalized coaching and support to help you succeed. What you'll get: One-on-one coaching sessions to help you identify and pursue your career goals; Tailored guidance on job search strategies, resume and cover letter development, and interview preparation; Access to a network of professionals in the field of neuroscience and neurotechnologies; Ongoing support and guidance to help you stay on track and achieve your goals. You can always schedule a free neurocareer consultation/coaching session with Dr. K at: https://neuroapproaches.as.me/free-neurocareer-consultation Also, find your support in the Your Support Station podcast with Dr. K here: https://www.neuroapproaches.org/podcast-2  

Link to bioRxiv paper: http://biorxiv.org/cgi/content/short/2022.12.11.519991v1?rss=1 Authors: Narayanan, R., Panwar, A., Butler, T. J., Cutrupi, A. N., Kennerson, M., Vucic, S., Balasubramaniem, A., Mangelsdorf, M., Wallace, R. H. Abstract: Mutations in TDP-43 are known to cause Amyotrophic Lateral Sclerosis (ALS) and Frontotemporal Dementia (FTD). TDP-43 binds to and regulates splicing of several RNA including Zmynd11. Zmynd11 is a transcriptional repressor and a potential E3 ubiquitin ligase family member, known for its role in neuron and muscle differentiation. Mutations in Zmynd11 have been associated with autism with significant developmental motor delays, intellectual disability, and ataxia. Here, we show that Zmynd11 is aberrantly spliced in the brain and spinal cord of transgenic mice overexpressing a mutant human TDP-43 (A315T), and that these changes occur before the onset of motor symptoms. Copy rights belong to original authors. Visit the link for more info Podcast created by Paper Player, LLC

Link to bioRxiv paper: http://biorxiv.org/cgi/content/short/2022.12.05.519172v1?rss=1 Authors: Byrd, A. T., Marmorale, L., Addison, V., Marcinowski, S., Buchan, J. R. Abstract: A key pathological hallmark in greater than 97% of all Amyotrophic Lateral Sclerosis (ALS) cases is the cytoplasmic mislocalization and aggregation of a nuclear RNA binding protein, TDP-43. Driving clearance of cytoplasmic TDP-43 reduces toxicity in various ALS models, though how TDP-43 clearance is regulated remains controversial. To address this, we conducted an unbiased yeast genome-wide screen using high-throughput dot blots to identify genes that affect TDP-43 levels. Our screen identified ESCRT complex factors, which induce membrane invagination (particularly at multi-vesicular bodies; MVBs) and K63-linked ubiquitination as key facilitators of TDP-43 endolysosomal clearance. TDP-43 co-localized and bound Rsp5/NEDD4 and ESCRT proteins, and perturbations to either increased TDP-43 aggregation and accumulation. NEDD4 also ubiquitinates TDP-43. Lastly, TDP-43 accumulation caused formation of "giant" MVBs which could reflect a pathological consequence of TDP-43 pertinent to ALS. Our studies shed light on endolysosomal-mediated cytoplasmic protein degradation, which likely impacts multiple substrates, and may be a target for novel ALS therapeutic strategies. Copy rights belong to original authors. Visit the link for more info Podcast created by Paper Player, LLC

Link to bioRxiv paper: http://biorxiv.org/cgi/content/short/2022.11.02.514252v1?rss=1 Authors: Bi, Y., Yan, X., Yacipi, N., Duan, W., Li, C., Thompson, M., Shan, Z., Bi, L. Abstract: Amyotrophic lateral sclerosis (ALS) is a fatal neurodegenerative disorder resulting from the progressive loss of both upper and lower motor neurons in the cerebral cortex, brainstem, and spinal cord. Currently, there are only two drugs, Riluzole (Rilutek) and Edaravone (Radicava), approved by FDA for ALS treatment. These two drugs are very expensive with only a few months of life extension. So far, there is no cure for ALS. Aberrant protein aggregation in motor neurons is an intracellular hallmark of ALS. The disturbance in protein homeostasis may contribute to the onset and progression of ALS. Autophagy plays an important role in degrading misfolded proteins and thereby preventing their aggregation. Pharmacological manipulation of autophagy has been proposed as a new therapeutic approach for treating ALS. IADB, a novel indole alkaloid derivative, has been reported to exert mitochondrial protection and cardioprotection through its autophagy-modulating potential. In our present study, we attempted to examine whether IADB has therapeutic potential in SOD1G93A-associated experimental models of ALS. We found that IADB could promote the clearance of SOD1G93A aggregates and reduce the overproduction of mitochondrial reactive oxygen species (ROS) in motor neuron-like NSC-34 cells transfected with SOD1G93A. We further examined the IADB in a mouse model of ALS. Administration of IADB started at the age of 55 days until the end stage of the disease. IADB treatment significantly increased LC3-II levels and decreased human SOD1 levels and p62 expression in the spinal cords of SOD1G93A mice, suggesting that IADB treatment could induce autophagy activation and promote clearance of mutant SOD1 aggregates in SOD1G93A mice. Moreover, IADB treatment could alleviate the activation of microglia and astrocytes and mitochondrial oxidative damage in the spinal cord of SOD1G93A mice. Finally, we demonstratedthat IADB treatment could improve motor performance and delay the onset and progression of the disease in a mouse model of ALS. The neuroprotective effects of IADB may mainly originate from its autophagy-promoting property. Copy rights belong to original authors. Visit the link for more info Podcast created by Paper Player, LLC

Link to bioRxiv paper: http://biorxiv.org/cgi/content/short/2022.11.02.514962v1?rss=1 Authors: Keifer, O., Gutierrez Gonzalez, J., Butt, M., Cramer, S., Bartus, R., Tansey, M., Deaver, D., Betourne, A., Boulis, N. Abstract: Riluzole is the only treatment known to improve survival in patients with Amyotrophic Lateral Sclerosis (ALS). However, oral riluzole efficacy is modest at best, further it is known to have large inter-individual variability of serum concentration and clearance, is formulated as an oral drug in a patient population plagued with dysphagia, and has known systemic side-effects like asthenia (limiting patient compliance) and elevated liver enzymes. In this context, we postulated that continuous intrathecal (IT) infusion of low doses of riluzole could provide consistent elevations of the drug spinal cord (SC) concentrations at or above those achieved with oral dosing, without increasing the risk for adverse events associated with systemic drug exposure or off-target side effects in the brain. We developed a formulation of riluzole for IT delivery and conducted our studies in purpose-bred hound dogs. Our non-GLP studies revealed that IT infusion alone was able to increase SC concentrations above those provided by oral administration, without increasing plasma concentrations. We then conducted two GLP studies that combined IT infusion with oral administration at human equivalent dose, to evaluate SC and brain concentrations of riluzole along with assessments of safety and tolerability. In the 6-week study, the highest IT dose (0.2 mg/hr) was well tolerated by the animals and increased SC concentrations above those achieved with oral riluzole alone, without increasing brain concentrations. In the 6-month study, the highest dose tested (0.4 mg/hr) was not tolerated and yielded SC significantly above those achieved in all previous studies. Our data show the feasibility and safety profile of continuous IT riluzole delivery to the spinal cord, without concurrent elevated liver enzymes, and minimal brain concentrations creating another potential therapeutic route of delivery to be used in isolation or in combination with other therapeutics. Copy rights belong to original authors. Visit the link for more info Podcast created by Paper Player, LLC

Amyotrophic lateral sclerosis (ALS) – also known as Lou Gehrig's disease – is a rapidly progressive, neurodegenerative disease.1 Those living with ALS eventually lose their ability to walk, dress, write, speak, swallow and eat.1 ALS can affect people of all races and ethnic backgrounds, but did you know that Veterans are twice as likely to develop ALS than those who haven't served in the military? This Veterans Day, we honor those who have served in the U.S. armed forces and thank them for the sacrifices they've made to protect our country. I had the extreme honor of speaking with Juan Reyes, a U.S. Air Force Veteran living with ALS and a MTPA Patient Ambassador, to share his story of living with ALS, discuss how he's helping to spread awareness of this devastating disease among Veterans, and how others living with the disease can help support the ALS community. Along with his wife of 33 years, Meg.

Link to bioRxiv paper: http://biorxiv.org/cgi/content/short/2022.10.24.513566v1?rss=1 Authors: de Majo, M., Koontz, M., Marsan, E., Salinas, N., Ramsey, A., Kuo, Y.-M., Seo, K., Li, H., Draeger, N. M., Leng, K., Kurnellas, M., Miyaoka, Y., Klim, J. R., Kampmann, M., Ward, M. E., Huang, E. J., Ullian, E. M. Abstract: Loss of function (LoF) of Tar-binding protein 43 (TDP-43) and mislocalization, together with TDP-43-positive and hyperphosphorylated inclusions, are found in postmortem tissue of Amyotrophic Lateral Sclerosis (ALS) and frontotemporal dementia (FTD) patients, including those carrying LoF variants in the progranulin gene (GRN). Modeling TDP-43 pathology has been challenging in vivo and in vitro. We present a 3D-induced pluripotent stem cell (iPSC)-derived paradigm - mature brain organoids (mbOrg) - composed of cortical-like-astrocytes (iA) and neurons (iN). When devoid of GRN, mbOrgs spontaneously recapitulate TDP-43 mislocalization, hyperphosphorylation and LoF phenotypes. Mixing-and-matching genotypes in mbOrgs showed that GRN-/- iA are drivers for TDP-43 pathology. Finally, we rescued TDP-43 LoF by adding exogenous progranulin, demonstrating a link between TDP-43 LoF and progranulin expression. In conclusion, we present an iPSC-derived platform that shows striking features of human TDP-43 proteinopathy and provides a tool for mechanistic modeling of TDP-43 pathology and patient-tailored therapeutic screening for FTD and ALS. Copy rights belong to original authors. Visit the link for more info Podcast created by Paper Player, LLC

Find a Place for Me: Embracing Love and Life in the Face of Death (Pact Press, November 1, 2022) is an award-winning memoir about facing a marriage's last act—a spouse's death—as a couple united in mind and holding hands. Author Deirdre Fagan, D.A., was married eleven years and had two young children when her forty-three-year-old husband Bob was diagnosed with Amyotrophic Lateral Sclerosis (ALS), also known as Lou Gehrig's Disease. ALS determined the journey their marriage would now take, but Bob and Deirdre were resolute in how they traversed their remaining months as a couple. Chronicling Bob's illness, Find a Place for Me is also the love story of a happy marriage filled with humor, honesty, and essential conversations, despite their tragic circumstances. In this moving and surprisingly funny book, Deirdre and Bob raise a glass to love and the life each of them has left while learning how to lovingly say goodbye.Find a Place for Me received a bronze medal in the 2022 Living Now Book Awards. An offshoot of the IPPY awards, one of the top awards given to independent publishers, the Living Now Book Award is given to books based on their outstanding ability to enrich readers' lives. Deirdre visits with Mark Alyn.

Find a Place for Me: Embracing Love and Life in the Face of Death (Pact Press, November 1, 2022) is an award-winning memoir about facing a marriage's last act—a spouse's death—as a couple united in mind and holding hands. Author Deirdre Fagan, D.A., was married eleven years and had two young children when her forty-three-year-old husband Bob was diagnosed with Amyotrophic Lateral Sclerosis (ALS), also known as Lou Gehrig's Disease. ALS determined the journey their marriage would now take, but Bob and Deirdre were resolute in how they traversed their remaining months as a couple. Chronicling Bob's illness, Find a Place for Me is also the love story of a happy marriage filled with humor, honesty, and essential conversations, despite their tragic circumstances. In this moving and surprisingly funny book, Deirdre and Bob raise a glass to love and the life each of them has left while learning how to lovingly say goodbye.Find a Place for Me received a bronze medal in the 2022 Living Now Book Awards. An offshoot of the IPPY awards, one of the top awards given to independent publishers, the Living Now Book Award is given to books based on their outstanding ability to enrich readers' lives. Deirdre visits with Mark Alyn.

Link to bioRxiv paper: http://biorxiv.org/cgi/content/short/2022.08.29.505610v1?rss=1 Authors: Broadhead, M. J., Doucet, K., Kantelberg, O. G., Zhu, F., Grant, S. G. N., Horrocks, M. H., Miles, G. B. Abstract: Cellular inclusions of hyperphosphorylated TAR-DNA-Binding Protein 43 (TDP-43) are a key hallmark of neurodegenerative diseases such as Amyotrophic Lateral Sclerosis (ALS). ALS is characterised by a loss of motor neurons in the brain and spinal cord that is preceded by early-stage changes in synaptic function that may be associated with TDP-43 pathology. However, there has been little characterisation of the synaptic expression of TDP-43 in spinal cord synapses. This study utilises a range of high-resolution and super-resolution microscopy techniques with immunolabelling, as well as an aptamer-based TDP-43 labelling strategy visualised with single-molecule localisation microscopy, to characterise and quantify the presence of phosphorylated TDP-43 (pTDP-43) in spinal cord synapses. We observe that TDP-43 is expressed in the majority of spinal cord synapses as nanoscale clusters as small as 60 nm in diameter. Synaptic TDP-43 expression is more frequently associated with presynaptic terminals than postsynaptic densities, and is more enriched in VGLUT1-associated synapses, compared to VGLUT2-associated synapses. Our nanoscopy techniques showed no difference in the subsynaptic expression of pTDP-43 in the ALS mouse model, SOD1G93a compared to healthy controls. This research characterizes the basic synaptic expression of TDP-43 with nanoscale precision and provides a framework with which to investigate the potential relationship between TDP-43 pathology and synaptic pathology in neurodegenerative diseases. Copy rights belong to original authors. Visit the link for more info Podcast created by PaperPlayer

Days before their 25th wedding anniversary, Lisa Valentine Clark lost her husband Christopher to Amyotrophic Lateral Sclerosis (ALS) after a four-year battle. While both Lisa and Clark had been big figures in the performing circle in their area, they were astonished and humbled by the support they got from the community, friends, family, and even strangers. While Chris slowly lost control of his body, his spirits remained high as he choose to keep ‘Living ‘til the end.” Together, their family leaned on faith, and just as they had heard time and time again in their improv classes, accepted the challenges thrown at them with a “Yes, and…” attitude. Lisa joins this episode of the Relentlessly Resilient podcast to share their story.  Even though we live in challenging times we can become Relentlessly Resilient as we lean on and learn from one another's experiences. Hosts Jennie Taylor and Michelle Scharf are no strangers to overcoming adversity; Michelle lost her husband to cancer, while Jennie's husband Major Brent Taylor was killed in the service of our country. Their stories bond them together and now listeners can join them weekly as they visit with others enduring challenges and who teach us how they are exercising resiliency, finding value in their grief, and purpose in moving forward.  Listen to the Relentlessly Resilient Podcast regularly on your favorite platform, at kslpodcasts.com, kslnewsradio.com, or on the KSL App. Join the Resilience conversation on Facebook at @RelentlesslyResilient and Instagram @RelentlesslyResilientPodcast. Produced by KellieAnn Halvorsen.See omnystudio.com/listener for privacy information.

In this interview with Dr. Michelle Peris, Dr. Patricia opens up about what events in her life triggered her to look deeper into what it really means to be healthy.  It began with a deceptively simple, yet powerful and not often not asked question, WHY?  Her father, a seemingly VERY healthy man, slowly lost all of his muscle function with the fatal condition Amyotrophic Lateral Sclerosis (ALS, or Lou Gherig's Disease)... WHY? Why did this athletic IRON MAN competitor, doing everything “right”, have this happen to him without any family history? A deep dive into the research started to unearth startling information not covered in her medical school and specialty residence training. With this new perspective, Dr. Patricia continued to ask the question WHY? with her patients, and even with her own health issues. Listen to this amazing journey of discovery, and the mind bending conclusions Dr. Patricia came to when transcending the boundaries of her medical training.   Here's how Dr. Peris describes the interview:   Dr. Patricia Mills is incredibly thorough and tenacious. Like many people, she's come to explore various realms of medicine through being forced to forge her own way when bandaid solutions are not addressing a root cause of disease.    In our conversation, Patricia breaks down the boundaries to discovering what she now calls the Threads of Truth; themes that repeat throughout the texts, proven with basic science at the cellular level that stand up to the test of time. Patricia embarks on an absolutely incredible deep dive on how we need to be very conscious consumers of health information because there is an abundance of information and opinions, which aren't always evidence-based.

This season (season 4) we are taking a deep dive into Degenerative Myelopathy which  is a common, merciless neurological disorder in senior German Shepherds that surfaces anywhere between 7 and 14 years of age and is seen more in males than females. It is a slow, progressive spinal cord disorder similar to Amyotrophic Lateral Sclerosis (ALS) in humans, which starts with a loss of balance and coordination that progresses to muscle weakness. Then, in time the dog will be unable to support himself, which will lead to paralysis resulting in quadriplegia or paraplegia. Eventually, death occurs from respiratory failure due to paralysis of muscles around the chest cavity.  There is no cure for Degenerative Myelopathy, but supportive care and Physical Therapy may slow down the progression of the disease. In this podcast, we'll share our experiences with DM and bring on guests who specialize in DM, mobility devices, and pain/anxiety relief experts. Our goal for this season of the #Lifewitholddogs podcast is to  arm you with as much DM knowledge as possible should your senior German Shepherd be stricken get it.DM blog post link:https://www.wpsgss.org/post/degenerative-myelopathy-dm-an-all-too-common-merciless-disease-in-senior-german-shepherdsWoody's Place Senior German Shepherd support group:https://www.facebook.com/groups/search/groups_home/?q=wpsgss%20degenerative%20myelopathy%20support%20groupYou can find Woody's Place Senior German Shepherd Sanctuary online at:www.wpsgss.orghttps://www.facebook.com/woodysplacesgsshttps://www.instagram.com/wpsgss/https://www.youtube.com/channel/UC7Tb1hKnOWEamQstkqAxEygWe would LOVE it if you could leave a thumbs up or comment! Please and Thank you!You can support our podcast by going to: (http://www.patreon.com/LifeWithOldDogs)Support the show

How much joy and encouragement would you have to give if you knew your time was short? My guest today is Tina. She is a long-time friend and was recently diagnosed with Amyotrophic Lateral Sclerosis (ALS), commonly known as Lou Gehrig's disease, is a progressive neuromuscular disease. ALS is characterized by progressive degeneration of motor nerve cells in the brain (upper motor neurons) and spinal cord (lower motor neurons). After going through an 18-month process Tina was given the news she has ALS and that it would one day take her life. Tina has made it her mission with the time, she has left to be a source of joy and encouragement. Join me as I try on Tina's very comfy slippers. •Please visit https://www.worldlovebank.com/ to learn more about WORLDLOVEBANK. LOVE after all is the most valuable asset, and WORLDLOVEBANK  will help you build emotional security. As we all know life is temporary... accidents happen. Keep your I love you's safe. •Remember when you walk in Other People's Shoes you get a different perspective!•Other People's Shoes would love your financial gift to help support the show click here•Have questions or want to give feedback call or text: 203-548-SHOE•If you enjoy the show consider subscribing on your favorite podcast platforms, so you don't miss an episode. We would also love it if you could leave us a review click here!•To hear other episodes go to:www.opspodcast.com•Social Media:**Facebook: Instagram: Twitter: ** @opspodcashow

In this podcast, we are joined by Indu Navar. Indu Navar is the CEO of Everything ALS, a company that prioritizes bringing awareness to Amyotrophic Lateral Sclerosis (ALS) and those who suffer from it. ALS is a neurological condition that affects the victim's motor neurons. This causes muscle atrophy all across the body, which can eventually cause suffocation and even death.    Listen now to learn about: The importance of diagnosing neurodegenerative diseases early. What happens to victims of ALS. What the typical onset age for ALS is. How ALS progresses in victims.  We don't know much about ALS and how to treat it. Indu Navar is dedicated to facilitating more investigation into this condition so that doctors can more effectively treat it. This episode explores how advocacy and citizen research plays an important role in solving ALS and conditions like it. To learn more about Indu Navar and her work at Everything ALS, visit www.everythingals.org. Episode also available on Apple Podcast: http://apple.co/30PvU9C

Human Endogenous Retroviruses (HERVs) comprise 8% of the human genome and are relics of ancient infections, some dating back to pre-human primates.  These resident viral elements can be awakened by viral infections, and have been shown to be tightly associated with diseases like Multiple Sclerosis (MS) and Amyotrophic Lateral Sclerosis (ALS).  New data suggest a role for HERVs in the neurological symptoms of long COVID. Today's podcast features a conversation with Jesus Martin-Garcia, CEO and Co-Founder of GeNeuro. New therapies target the rogue proteins arising from these ancient viruses, and show promise in treating, if not reversing, disease progression.  Follow GeNeuro on TwitterGeNeuro Website    http://www.geneuro.com/YouTube Videos of their technology

Acquired neurologic conditions can lead to functional challenges and changes that might increase risk for suicide. In this episode, Dr. Jordan Wyrwa and Dr. Lisa Brenner discuss three recent research papers on suicide rates among Veterans with Traumatic Brain Injury (TBI), Amyotrophic Lateral Sclerosis (ALS) and Stroke. They talk about the similarities and differences of how these conditions impact mental health and offer guidance to providers on suicide risk screening and lethal means safety. Learn more from the resources below. Articles Discussed: Suicide and Traumatic Brain Injury Among Individuals Seeking Veterans Health Administration Services Between Fiscal Years 2006 and 2015 Suicide Among Veterans with Amyotrophic Lateral Sclerosis  Suicide After Stroke in the US Veteran Health Administrative Population Lethal Means Safety for Providers: Information on lethal means safety  Free training on lethal means safety   Guest Bios:   Lisa A. Brenner, Ph.D., is a Board-Certified Rehabilitation Psychologist, a Professor of Physical Medicine and Rehabilitation (PM&R), Psychiatry, and Neurology at the University of Colorado, Anschutz Medical Campus, and the Director of the Department of Veterans Affairs Rocky Mountain Mental Illness Research, Education, and Clinical Center. She is also Vice Chair of Research for the Department of PM&R. Jordan Wyrwa, DO, is a Board-Eligible Fellow Physician in Pediatric Rehabilitation Medicine at Children's Hospital Colorado. He is a recent graduate of the University of Colorado, PM&R Residency Program.

Three months ago we did a podcast with Randy Curits about his recent diagnosis of ALS in March and what it was like for someone who studies and cares for people living with serious illness, to now be someone who is living with serious illness.  It was one of our favorite podcasts we've done, but also got us to think “wait, how come we've never done a podcast on ALS?” We fix that on today's podcast.  We've invited Elizabeth Lindenberger and Kara Bischoff to talk about what every geriatrician and palliative care clinician should know about ALS.    Topics include: prognosis in ALS, disease modifying therapies (and when/if to discontinue, advance care planning in ALS, the role of embedding geriatrics/palliative care in ALS clinics, interventions in ALS (noninvasive ventilation, PEG tubes, and trachs), and symptom management as the disease progress.  So take a listen and if you want to take a deeper dive, take a look at these articles: Embedded Palliative Care for Amyotrophic Lateral Sclerosis: A Pilot Program and Lessons Learned Top Ten Tips Palliative Care Clinicians Should Know About Amyotrophic Lateral Sclerosis  

My name is Carly and I am a senior here at the University of Arizona majoring in Neuroscience with minors in Spanish and Biochemistry! I am an undergraduate researcher in Dr. Daniela Zarnescu's lab where we study the neurodegenerative disease Amyotrophic Lateral Sclerosis (ALS) using fly models. Our research looks at various celular and genetic mechanisms in the disease and also potential treatments for ALS. Some other things I do outside of lab includes being a Science and Spanish tutor and I am the co-president of a premedical club on campus. My hobbies include knitting, working out, and cooking (specifically Middle Eastern and Mexican food).

In this episode, we review the high-yield topic of Amyotrophic Lateral Sclerosis (ALS) from the Neurology section. Follow Medbullets on social media: Facebook: www.facebook.com/medbullets Instagram: www.instagram.com/medbulletsofficial Twitter: www.twitter.com/medbullets

Degenerative Myelopathy (DM) is a common, merciless neurological disorder in senior German Shepherds that surfaces anywhere between 7 and 14 years of age, and is seen more in males than females. It is a slow, progressive spinal cord disorder that is similar to Amyotrophic Lateral Sclerosis (ALS) in humans.In this #Lifewitholddogs podcast episode, we share our experiences with DM, products we use for supportive care, physical therapies that help keep our seniors with DM comfortable, and share the mistakes I (Dawn) made with Woody, my very first DM dog.Our correlating blog post this week has lots of imagery about DM and links for helpful supportive care products, so be sure to visit to get that additional information.https://www.wpsgss.org/post/degenerative-myelopathy-dm-an-all-too-common-merciless-disease-in-senior-german-shepherdsWe also have a Degenerative Myelopathy support group on Facebook where we share information about DM and you can post as well! It's free to join.https://www.facebook.com/groups/2009914109023556You can find Woody's Place Senior German Shepherd Sanctuary online at:www.wpsgss.orghttps://www.facebook.com/woodysplacesgsshttps://www.instagram.com/wpsgss/https://www.youtube.com/channel/UC7Tb1hKnOWEamQstkqAxEygSupport the show (http://www.patreon.com/#LifeWithOldDogs)

When teacher and performer David Martin found out that his friend and music director Chris Clark was diagnosed with Amyotrophic Lateral Sclerosis (ALS) in early 2016, he was devastated. But Chris’s pervasively optimistic outlook on tackling the terminal diagnosis changed David’s own life outlook. David launched a performance program to educate the public and raise awareness of ALS while celebrating the lives of its victims, which included Chris in 2020. “BeatALS Benefit” concerts and programs help unite schools, communities, and businesses in a concentrated effort to beat ALS through the songs of The Beatles. With upcoming concerts in October 2021, Dave joins the Relentlessly Resilient podcast to discuss the BeatALS programs, invite listeners to donate or participate in the concerts, and share the stories of resilience he has learned from ALS patients who “Take a Sad Song and Make it Better.” Even though we live in challenging times we can become Relentlessly Resilient as we lean on and learn from one another’s experiences. Hosts Jennie Taylor and Michelle Scharf are no strangers to overcoming adversity; Michelle lost her husband to cancer, while Jennie’s husband Major Brent Taylor was killed in the service of our country. Their stories bond them together and now listeners can join them weekly as they visit with others enduring challenges and who teach us how they are exercising resiliency, finding value in their grief, and purpose in moving forward. Listen to the Relentlessly Resilient Podcast regularly on your favorite platform, at kslpodcasts.com, kslnewsradio.com, or on the KSL App. Join the Resiliences conversation on Facebook at @RelentlesslyResilient and Instagram @RelentlesslyResilientPodcast. Produced by KellieAnn Halvorsen.See omnystudio.com/listener for privacy information.

James Lange is a nationally recognized IRA, a 401(k) and retirement plan distribution expert, and the president and founder of the Roth IRA Institute, which helps financial professionals and IRA and retirement plan owners to get the most from their retirement plans using Roth IRA conversions as an integral part of the planning strategy. More importantly, his ideas have affected my own thinking about investing, particularly the use of retirement accounts. In this interview we discuss all these things as well as his recent book, Beating the New Death Tax, which he is giving away to WCI listeners. I really like his writing. He is not afraid to get into the weeds and give hard recommendations. So many books out there are so full of fluff. His are not. If you're into the details, this is an episode you will enjoy. Learn more here https://www.whitecoatinvestor.com/which-assets-to-spend-first/  This episode of The White Coat Investor is sponsored by Biohaven Pharmaceuticals. Biohaven is a commercial-stage biopharmaceutical company with innovative therapies designed to improve the lives of patients with debilitating neurological and neuropsychiatric diseases, including rare disorders. Biohaven offers a broad pipeline of late-stage product candidates across three distinct mechanistic platforms, including developing therapies for patients with Amyotrophic Lateral Sclerosis (ALS), Alzheimer's, and obsessive compulsive disorder (OCD). The FDA also recently gave Biohaven's Nurtec® ODT (rimegepant) its second indication. To discover more about Nurtec ODT and Biohaven's neuroinnovative portfolio of treatments in development, visit https://www.biohavenpharma.com  The White Coat Investor has been helping doctors with their money since 2011. Our free financial planning resource covers a variety of topics from doctor mortgage loans and refinancing medical school loans to physician disability insurance and malpractice insurance. Learn about loan refinancing or consolidation, explore new investment strategies, and discover loan programs for specifically aimed at helping doctors. If you're a high-income professional and ready to get a "fair shake" on Wall Street, The White Coat Investor channel is for you! Main Website: https://www.whitecoatinvestor.com  YouTube: https://www.whitecoatinvestor.com/youtube  Student Loan Advice: https://studentloanadvice.com  Facebook: https://www.facebook.com/thewhitecoatinvestor  Twitter: https://twitter.com/WCInvestor  Instagram: https://www.instagram.com/thewhitecoatinvestor  Subreddit: https://www.reddit.com/r/whitecoatinvestor  Online Courses: https://whitecoatinvestor.teachable.com  Newsletter: https://www.whitecoatinvestor.com/free-monthly-newsletter 

The point of residency is to learn how to be a good doctor. It's not to try to get rich. But for new residents there are a few financial chores you need to take care of during residency. Don't drop the ball on these. Get in the habit of saving something each month from your paycheck, know where your money is going, and make sure you have critical insurance in place. We discuss these chores in more detail in this episode. For our non resident listeners we also answer some of your questions about mega backdoor Roth IRAs, DFA ETFs vs Vanguard ETFs, getting rid of your whole life insurance policy, everyone's favorite tax form - form 8606, and cash balance plans. This episode of The White Coat Investor is sponsored by Biohaven Pharmaceuticals. Biohaven is a commercial-stage biopharmaceutical company with innovative therapies designed to improve the lives of patients with debilitating neurological and neuropsychiatric diseases, including rare disorders. Biohaven offers a broad pipeline of late-stage product candidates across three distinct mechanistic platforms, including developing therapies for patients with Amyotrophic Lateral Sclerosis (ALS), Alzheimer's, and obsessive compulsive disorder (OCD). The FDA also recently gave Biohaven's Nurtec® ODT (rimegepant) its second indication. To discover more about Nurtec ODT and Biohaven's neuroinnovative portfolio of treatments in development, visit https://www.biohavenpharma.com  The White Coat Investor has been helping doctors with their money since 2011. Our free financial planning resource covers a variety of topics from doctor mortgage loans and refinancing medical school loans to physician disability insurance and malpractice insurance. Learn about loan refinancing or consolidation, explore new investment strategies, and discover loan programs for specifically aimed at helping doctors. If you're a high-income professional and ready to get a "fair shake" on Wall Street, The White Coat Investor channel is for you! Main Website: https://www.whitecoatinvestor.com  YouTube: https://www.whitecoatinvestor.com/youtube  Student Loan Advice: https://studentloanadvice.com  Facebook: https://www.facebook.com/thewhitecoatinvestor  Twitter: https://twitter.com/WCInvestor  Instagram: https://www.instagram.com/thewhitecoatinvestor  Subreddit: https://www.reddit.com/r/whitecoatinvestor  Online Courses: https://whitecoatinvestor.teachable.com  Newsletter: https://www.whitecoatinvestor.com/free-monthly-newsletter 

Becoming a new attending is a complicated time in your financial life. That first year out of training is probably the most important year of your financial life. What you do with your financial life in that first year, can predict the next 30 or 40 years of your financial life with surprising accuracy. In this episode we go over the financial priorities of a new attending, what you should be focusing on and in what order, from insurance and student loans to retirement accounts and mortgages. For those who don't fall into this category we answer listener questions about asset allocations for 529 accounts, having multiple 401k(s), benefits of a side gig as a business owner, improving your cyber security and avoiding identity theft, and if the pandemic continues to affect the income recertification for IDR. This episode of The White Coat Investor is sponsored by Biohaven Pharmaceuticals. Biohaven is a commercial-stage biopharmaceutical company with innovative therapies designed to improve the lives of patients with debilitating neurological and neuropsychiatric diseases, including rare disorders. Biohaven offers a broad pipeline of late-stage product candidates across three distinct mechanistic platforms, including developing therapies for patients with Amyotrophic Lateral Sclerosis (ALS), Alzheimer's, and obsessive compulsive disorder (OCD). The FDA also recently gave Biohaven's Nurtec® ODT (rimegepant) its second indication. To discover more about Nurtec ODT and Biohaven's neuroinnovative portfolio of treatments in development, visit https://www.biohavenpharma.com  The White Coat Investor has been helping doctors with their money since 2011. Our free financial planning resource covers a variety of topics from doctor mortgage loans and refinancing medical school loans to physician disability insurance and malpractice insurance. Learn about loan refinancing or consolidation, explore new investment strategies, and discover loan programs for specifically aimed at helping doctors. If you're a high-income professional and ready to get a "fair shake" on Wall Street, The White Coat Investor channel is for you! Main Website: https://www.whitecoatinvestor.com  YouTube: https://www.whitecoatinvestor.com/youtube  Student Loan Advice: https://studentloanadvice.com  Facebook: https://www.facebook.com/thewhitecoatinvestor  Twitter: https://twitter.com/WCInvestor  Instagram: https://www.instagram.com/thewhitecoatinvestor  Subreddit: https://www.reddit.com/r/whitecoatinvestor  Online Courses: https://whitecoatinvestor.teachable.com  Newsletter: https://www.whitecoatinvestor.com/free-monthly-newsletter 

"Average Joe" is frequently poor because of his car. For most middle-class Americans, the reason they are not millionaires is sitting in the driveway. It is a really important concept to understand, that we are wasting a lot of money on cars. We simply consume it. You don't have to do that. Here is the other truth that makes it very difficult to talk about this subject, https://www.whitecoatinvestor.com/drive-a-beater-get-rich/ , most doctors make enough money that they can drive a very nice car and still be financially successful. So, despite the fact that this is an important aspect of your financial life if you're middle-class, it doesn't matter nearly as much for doctors. However, in this episode we discuss how to know how much car you can afford, debunk some of the reasons why doctors justify getting new cars instead of driving something inexpensive, and talk about the most economical way to pay for your transportation. For those who have their vehicle situation all figured out, we also answer several listener questions about 457s, ETFs, and mutual funds. This episode of The White Coat Investor is sponsored by Biohaven Pharmaceuticals. Biohaven is a commercial-stage biopharmaceutical company with innovative therapies designed to improve the lives of patients with debilitating neurological and neuropsychiatric diseases, including rare disorders. Biohaven offers a broad pipeline of late-stage product candidates across three distinct mechanistic platforms, including developing therapies for patients with Amyotrophic Lateral Sclerosis (ALS), Alzheimer's, and obsessive compulsive disorder (OCD). The FDA also recently gave Biohaven's Nurtec® ODT (rimegepant) its second indication. To discover more about Nurtec ODT and Biohaven's neuroinnovative portfolio of treatments in development, visit https://www.biohavenpharma.com  The White Coat Investor has been helping doctors with their money since 2011. Our free financial planning resource covers a variety of topics from doctor mortgage loans and refinancing medical school loans to physician disability insurance and malpractice insurance. Learn about loan refinancing or consolidation, explore new investment strategies, and discover loan programs for specifically aimed at helping doctors. If you're a high-income professional and ready to get a "fair shake" on Wall Street, The White Coat Investor channel is for you! Main Website: https://www.whitecoatinvestor.com  YouTube: https://www.whitecoatinvestor.com/youtube  Student Loan Advice: https://studentloanadvice.com  Facebook: https://www.facebook.com/thewhitecoatinvestor  Twitter: https://twitter.com/WCInvestor  Instagram: https://www.instagram.com/thewhitecoatinvestor  Subreddit: https://www.reddit.com/r/whitecoatinvestor  Online Courses: https://whitecoatinvestor.teachable.com  Newsletter: https://www.whitecoatinvestor.com/free-monthly-newsletter 

Dr. Anh Bui ran in high school and at the collegiate level where she found herself injured often. She grew up in San Leandro, CA and was raised in a first-generation immigrant family. San Leandro was a melting pot of low-to-median income households with pockets of crime, and under-resourced and underprivileged youth. Dr. Bui recalls few resources being available to her to manage running injuries and was always in the position to run through pain or sit out and “rest” the entire season. She competed in cross country and track at UC San Diego where her injuries continued to manifest, and while she had access to athletic trainers, she was never exposed to physical therapists for long-term injury prevention. While studying abroad at the Australian Institute of Sport—the Aussie equivalent of US Olympic Training Centers—she became interested in physiology, human performance and biomechanics. While studying under world-renowned exercise physiologists, Dr. Bui knew right away that she wanted to work with endurance athletes. Specifically to correct poor movement patterns and prevent injury. Dr. Bui refers to physical therapy as her second career in life, as her first was in research and academia. After earning her Bachelors of Science in biology at UC San Diego, she worked as a neuroscience research associate at the Ludwig Institute for Cancer Research. She studied neurodegenerative disease, specifically Amyotrophic Lateral Sclerosis (ALS). While shadowing a physician and physical therapist who worked with ALS patients, Dr. Bui realized she wanted to become a physical therapist; she wanted to help patients restore function and mobility. Additionally, her background in research and academia compels her to utilize evidence-based research to her practice. Dr. Bui completed her Doctor of Physical Therapy at Columbia University in NYC. She participated in unique electives including advanced orthopedics, management of the running athlete, and women's health. She held leadership roles at Columbia's RunLab clinic, performing running gait evaluations and providing individualized exercise programs to high-level runners. Dr. Bui's favorite aspect of RunLab was employing running gait analysis technology to help runners prevent injury and improve performance. She continued to add to her running gait analysis repertoire during her sports residency in Boulder, CO, which placed her in the mecca of endurance athletes On the running front, you can find Dr. Bui logging tons of miles around the Bay Area. She is coached remotely by Boulder Underground and continues to race in sub-elite 5k- marathon races. Learn more at www.runresilientlydpt.com. Follow Matt: Instagram - @rambling_runner Twitter - @rambling_runner Rambling Runner Podcast Community Corner private Facebook group - www.facebook.com/groups/125544686229661

• Take Dr. Berg's Free Keto Mini-Course! • How to Bulletproof your Immune System Course • Dr. Berg's Beginner Guide to Healthy Keto & Intermittent Fasting Plan • Intermittent Fasting Basics for Beginners • Dr. Berg's Healthy Ketogenic Diet Basics: Step 1: https://youtu.be/vMZfyEy_jpI Step 2: https://youtu.be/mBqpaAKtnXE My recommendations if you have ALS. Dr. Eric Berg DC Bio: Dr. Berg, 51 years of age is a chiropractor who specializes in weight loss through nutritional & natural methods. His private practice is located in Alexandria, Virginia. His clients include senior officials in the U.S. government & the Justice Department, ambassadors, medical doctors, high-level executives of prominent corporations, scientists, engineers, professors, and other clients from all walks of life. He is the author of The 7 Principles of Fat Burning. Dr. Berg's Website: http://bit.ly/37AV0fk Dr. Berg's Recipe Ideas: http://bit.ly/37FF6QR Dr. Berg's Reviews: http://bit.ly/3hkIvbb Dr. Berg's Shop: http://bit.ly/3mJcLxg Dr. Berg's Bio: http://bit.ly/3as2cfE Dr. Berg's Health Coach Training: http://bit.ly/3as2p2q Facebook: https://www.facebook.com/drericberg Messenger: https://www.messenger.com/t/drericberg Instagram: https://www.instagram.com/drericberg/ YouTube: http://bit.ly/37DXt8C

What is it like working as a therapist in a multidisciplinary clinic? How is the integrated model of care applied to complex degenerative diseases? Learn this and more as Parm interviews physical therapist Katey Burke and speech-language pathologist Stacey Sullivan about their experience working in a multidisciplinary clinic for Amyotrophic Lateral Sclerosis (ALS). Together they dive into the ins & outs of patient-centered care, including coordination and communication, billing, and initiating difficult conversations with patients.   The Degenerative Diseases Special Interest Group is part of the Academy of Neurologic Physical Therapy – www.neuropt.org. 

Humbling conversation with, Eric Roy. Eric was recently diagnosed with Amyotrophic Lateral Sclerosis (ALS), a disease that is very common in his family. Eric explains what ALS is and goes into detail about how the disease is rapidly attacking his body. Eric talks about some recent medical trials that have showed some promising results, but more research and funding is needed. Eric and his family need your support during these challenging times. The family has started a GoFundMe and the funds collected will assist Eric and his family in purchasing proper medical care, mobility/communication equipment, medications not covered by insurance, and in home nursing support. Please visit Eric's GoFundMe down below. Any donation will be greatly appreciated. Link below. https://www.gofundme.com/f/eric-roy-facing-als?utm_source=customer&utm_medium=sms&utm_campaign=p_cp%20share-sheet&fbclid=IwAR0N68lb2ooB19rlTPOYlAyWuxWk1mmqAoElUdj3M4QG1mXZwiJ1Ggjooxo

Amyotrophic Lateral Sclerosis (ALS), also known as Lou Gehrig’s disease, is a progressive motor neuron disease.“In July 2018, that is, within six months, he developed paraparesis of both arms and also suffered from cramps in the shoulder girdle and hand muscles,” wrote the authors. “By August 2018, the patient was severely impaired in everyday life activities.”I first read about this case by Wirsching and colleagues in the journal Clinical Case Reports. His spinal test was positive for Lyme disease a high white count and positive labs tests for Lyme disease. He was treated with a 3 week course of intravenous antibiotics without gains. The author concluded he suffered from ALS instead of Lyme disease.“It is vital to exclude potentially treatable diseases in the differential diagnostic work-up of all patients not to miss seldom, but treatable differential diagnoses such as neuroborreliosis,” the authors concluded.Wirsching I, Ort N, Uceyler N. ALS or ALS mimic by neuroborreliosis-A case report. Clin Case Rep. Jan 2020;8(1):86-91. doi:10.1002/ccr3.2569You can hear more about these cases through his blogs, social media, and YouTube. Sign up for our newsletter to keep up with these cases.How to Connect with Dr. Daniel Cameron:Check out his website: https://www.DanielCameronMD.com/Call his office: 914-666-4665Email him: DCameron@DanielCameronMD.com Send him a request: https://danielcameronmd.com/contact-daniel-cameron-md/Like him on Instagram: https://www.instagram.com/drdanielcameron/Join his Facebook group: https://www.facebook.com/danielcameronmd/Follow him on Twitter: https://twitter.com/DrDanielCameronSign up for his newsletter: https://www.DanielCameronMD.com/Subscribe and ring the bell: https://www.youtube.com/user/danielcameronmd/ Leave a review on iTunes or wherever else you get your podcasts.We, of course, hope you’ll join the conversation, connect with us and other readers, ask questions, and share your insights. Dr. Cameron is a Lyme disease expert and the author "Inside Lyme: An expert's guide to the science of Lyme disease." He has been treating adolescents and adults for more than 30 years.Please remember that the advice given is general and not intended as specific advice as to any particular patient. If you require specific advice, then please seek that advice from an experienced professional.

With an extensive scientific background in neurodegeneration, and especially in Amyotrophic Lateral Sclerosis (ALS), Kim is driven to move safe and effective therapies to people with ALS or with other rare diseases across the globe. After two postdocs in academia, Kim set out to provide science consultancy to biotech, academia, and patient organizations. In addition, as a career coach, she feels strongly about inspiring and empowering academic scientists to obtain the careers that they want, either within or beyond academia. Kim has worked on a short film about ALS called The First Color: https://www.instagram.com/the_first_color_movie/ Kim is in the midst of setting up an online platform for (academic) career development: http://kimu.info/ More updates about this platform are to follow! Episode music - Funkorama by Kevin MacLeod Link: https://incompetech.filmmusic.io/song/3788-funkorama License: http://creativecommons.org/licenses/by/4.0/ *Extra sounds provided by baby Emmanuelle Sophia, sorry for the interference! --- Send in a voice message: https://anchor.fm/macademia/message

In this episode, we review the high-yield topic of Amyotrophic Lateral Sclerosis (ALS) from the Basic Science section. --- Send in a voice message: https://anchor.fm/orthobullets/message

Dr. Christen Shoesmith and Dr. Colleen O’Connell discuss the first Canadian guideline on the care and management of patients with amyotrophic lateral sclerosis (ALS). Dr. Shoesmith and Dr. O'Connell are two of the authors of the guideline, which is intended for ALS clinicians, allied health professionals and primary care providers and includes a patient-focused approach to care, with attention to holistic and emotional aspects of well-being. Dr. Christen Shoesmith is a neurologist and medical director of the Motor Neuron Disease Clinic at London Health Sciences Centre in London, Ontario. She is also chair of the ALS guidelines working group. Dr. Colleen O’Connell is a physical medicine and rehabilitation physician at the Stan Cassidy Rehabilitation Centre in Fredericton, New Brunswick. The clinical practice guideline is published in CMAJ: www.cmaj.ca/lookup/doi/10.1503/cmaj.191721 ----------------------------------- Subscribe to CMAJ Podcasts on Apple Podcasts, iTunes, Google Play, Stitcher, Overcast, Instacast, or your favourite aggregator. You can also follow us directly on our SoundCloud page or you can visit www.cmaj.ca/page/multimedia/podcasts.

How do you reframe a terminal disease as a life-limiting experience? In this episode of Defining Moments, guest host Dr. Erika Kirby speaks with Dr. Chad McBride and Dr. Kathy Miller on how they’ve been co-narrating Chad’s life in the wake of his diagnosis with amyotrophic lateral sclerosis (ALS), commonly referred to as Lou Gehrig’s disease. In raw and honest form, Chad reflects on the diagnosis and its impact. Together, Chad and Kathy describe their joint efforts of legacy leaving and memoir writing. Beyond clarifying these narrative endeavors, Chad and Kathy challenge listeners to cherish relationships lost and found. Dr. McBride and Dr. Kirby are Professors in the Department of Communication Studies at Creighton University. Dr. Miller is a retired academician who now writes fiction and nonfiction professionally. You can read more about Dr. McBride’s ALS experiences in Psychology Today at: https://www.psychologytoday.com/us/blog/medical-humanities-mamas/202008/experiencing-the-unimaginable-dying-and-leaving-your-child

Link to bioRxiv paper: http://biorxiv.org/cgi/content/short/2020.10.08.330894v1?rss=1 Authors: Don, E. K., Maschirow, A., Radford, R. A. W., Scherer, N. M., Vidal-Itriago, A., Hogan, A., Maurel, C., Formella, I., Stoddart, J. J., Hall, T. E., Lee, A., Shi, B., Cole, N. J., Laird, A. S., Badrock, A. P., Chung, R. S., Morsch, M. Abstract: Amyotrophic lateral sclerosis (ALS) is a form of motor neuron disease (MND) that is characterized by the progressive loss of motor neurons within the spinal cord, brainstem and motor cortex. Although ALS clinically manifests as a heterogeneous disease, with varying disease onset and survival, a unifying feature is the presence of ubiquitinated cytoplasmic protein inclusion aggregates containing TDP-43. However, the precise mechanisms linking protein inclusions and aggregation to neuronal loss are currently poorly understood. Bimolecular Fluorescence Complementation (BiFC) takes advantage the association of fluorophore fragments (non-fluorescent on their own) that are attached to an aggregation prone protein of interest. Interaction of the proteins of interest allows for the fluorescent reporter protein to fold into its native state and emit a fluorescent signal. Here, we combined the power of BiFC with the advantages of the zebrafish system to validate, optimize and visualize of the formation of ALS-linked aggregates in real time in a vertebrate model. We further provide in vivo validation of the selectivity of this technique and demonstrate reduced spontaneous self-assembly of the non-fluorescent fragments in vivo by introducing a fluorophore mutation. Additionally, we report preliminary findings on the dynamic aggregation of the ALS-linked hallmark proteins Fus and TDP-43 in their corresponding nuclear and cytoplasmic compartments using BiFC. Overall, our data demonstrates the suitability of this BiFC approach to study and characterize ALS-linked aggregate formation in vivo. Importantly, the same principle can be applied in the context of other neurodegenerative diseases and has therefore critical implications to advance our understanding of pathologies that underlie aberrant protein aggregation. Copy rights belong to original authors. Visit the link for more info

The Ice Bucket Challenge swept the United States beginning in the summer of 2014, spreading awareness and raising funds for research addressing Amyotrophic Lateral Sclerosis (ALS). While videos of dripping celebrities and soaked politicians make for lighthearted entertainment, the facts surrounding ALS carry much more weight. FOX SLP Shannon Stocks covers ALS treatment by a speech-language pathologist. Listen: Apple Podcasts | Google Podcasts | Google Play | Stitcher  | TuneIn | Other Android Apps Read more from Shannon Stocks, MS, CCC-SLP here.

Link to bioRxiv paper: http://biorxiv.org/cgi/content/short/2020.08.26.268631v1?rss=1 Authors: Garone, M. G., Birsa, N., Rosito, M., Salaris, F., Mochi, M., de Turris, V., Nair, R. R., Cunningham, T. J., Fisher, E. M. C., Fratta, P., Rosa, A. Abstract: Mutations in RNA-binding proteins (RBPs) have been genetically associated with the motoneuron disease Amyotrophic Lateral Sclerosis (ALS). Using both human induced Pluripotent Stem Cells and mouse models, we found that FUS-ALS causative mutations have a profound impact on a network of RBPs, including two relevant factors with important roles in neuronal RNA metabolism: HuD and FMRP. Mechanistically, cytoplasmic localization of mutant FUS leads to upregulation of HuD levels through competition with FMRP for HuD 3'UTR binding. In turn, increased HuD levels overly stabilize the transcript levels of its targets, NRN1 and GAP43. As a consequence, mutant FUS motoneurons show altered axon branching and growth upon injury. Abnormal axon branching and regrowth in FUS mutant motoneurons could be rescued by dampening NRN1 levels. Since similar phenotypes have been previously described in SOD1 and TDP-43 mutant models, aberrant axonal growth and branching might represent broad early events in the pathogenesis of ALS. Copy rights belong to original authors. Visit the link for more info

When Mandi Bailey's stepdad, Fred Drinkwater, was diagnosed with Amyotrophic Lateral Sclerosis (ALS) in 2017 it was a fast and furious two years. Every day Fred experienced a decline. Mandi's mom, Susan Drinkwater, struggled to keep up with the demands of the disease. One day they were planning for their golden years and the next day they were planning for how to get through the minutes and hours of each day to keep up with the demands of ALS. Mandi was a secondary caregiver for Fred and emotional support for her mom. She remains strong support for her mom. Fred was a Vietnam Veteran. He was service-connected for ALS. For reasons unknown, veterans are more than twice as likely to get ALS than non-veterans. If you are a veteran with service-connected ALS and need some guidance on VA resources and Care this is a useful tool: Thinking Through VA Benefits and VA Care: A Resource for Veterans with ALS & Their Caregivers After Fred's death, Mandi committed to putting her efforts into ALS advocacy for viable treatments and a cure. She has a Call to Action. She asks listeners to help by contacting your senator and representative in Washington, D.C. to support this legislation: H.R.7071: Accelerating Access to Critical Therapies for ALS Act Mandi advocates with the following organizations and invites others to join her: ALS Therapy Development Institute I Am ALS --- Send in a voice message: https://anchor.fm/thiscaregiverlife/message

Talk to a Dr. Berg Keto Consultant today and get the help you need on your journey (free consultation). Call 1-540-299-1557 with your questions about Keto, Intermittent Fasting, or the use of Dr. Berg products. Consultants are available Monday through Friday from 8 AM to 10 PM EST. Saturday & Sunday from 9 AM to 6 PM EST. USA Only. Get Dr. Berg's Veggie Solution today! • Flavored (Sweetened) - https://shop.drberg.com/veggie-solution-flavored-sweetened?utm_source=Podcast&utm_medium=AGM(Anchor) • Plain (Unflavored) - https://shop.drberg.com/veggie-solution-plain?utm_source=Podcast&utm_medium=AGM(Anchor) Take Dr. Berg's Free Keto Mini-Course! In this podcast, we're going to talk about amyotrophic lateral sclerosis (ALS) or Lou Gehrig's disease. I want to give you some natural remedies that may be able to help you if you have this disease. What is amyotrophic lateral sclerosis? — This is a rapidly progressive neurodegenerative disorder. ALS symptoms: • Muscle wasting • Difficulty with speech • Respiratory failure • Atrophy of the muscles How to help improve amyotrophic lateral sclerosis: • 20,000 IUs of vitamin D • Ketones (get on the healthy ketogenic diet, take MCT oil) • Intermittent fasting • Zinc/Copper • B12 • Vitamin E • Omega 3 (DHA) • Get a good water filter • Eat organic foods Vitamin D: https://bit.ly/3dW1Dso, https://bit.ly/38unW7G Dr. Eric Berg DC Bio: Dr. Berg, 51 years of age is a chiropractor who specializes in weight loss through nutritional & natural methods. His private practice is located in Alexandria, Virginia. His clients include senior officials in the U.S. government & the Justice Department, ambassadors, medical doctors, high-level executives of prominent corporations, scientists, engineers, professors, and other clients from all walks of life. He is the author of The 7 Principles of Fat Burning. FACEBOOK: fb.me/DrEricBerg?utm_source=Podcast&utm_medium=Anchor TWITTER: http://twitter.com/DrBergDC?utm_source=Podcast&utm_medium=Post&utm_campaign=Daily%20Post YOUTUBE: http://www.youtube.com/user/drericberg123?utm_source=Podcast&utm_medium=Anchor DR. BERG'S SHOP: https://shop.drberg.com/?utm_source=Podcast&utm_medium=Anchor MESSENGER: https://www.messenger.com/t/drericberg?utm_source=Podcast&utm_medium=Anchor DR. BERG'S VIDEO BLOG: https://www.drberg.com/blog?utm_source=Podcast&utm_medium=Anchor

On this bonus episode, Continuing On, Mar interviews her husband, Tom, about his interest in oil painting. Talent v Effort. Mar and Tom have been married for nearly forty years. Tom had encephalitis in 1993. She has been caring for him since then. To know them is to know they are partners in life, and for life. Spouses first, caregiver, and care recipient second. Encephalitis, a brain infection, impacted Tom's working memory and executive functioning. It did not, however, affect his optimistic, positive outlook on life. Even after a diagnosis of service-connected Amyotrophic Lateral Sclerosis (ALS) in 2010, his spirit remains indomitable. He doesn't give in. He doesn't give up. Take a listen as he shares his take on why painting matters, and matter, to him. To see some of his paintings visit Mar's Fine Art America website. Prints are available for sale. Among other things, Mar shares their journey on her blog. --- Send in a voice message: https://anchor.fm/thiscaregiverlife/message

Link to bioRxiv paper: http://biorxiv.org/cgi/content/short/2020.04.27.064063v1?rss=1 Authors: Demy, D. L., Campanari, M.-L., Munoz-Ruiz, R., Durham, H. D., Gentil, B., Kabashi, E. Abstract: Neurofilaments (NFs), a major cytoskeletal component of motor neurons, play a key role in their differentiation, establishment and maintenance of their morphology and mechanical strength. The de novo assembly of these neuronal intermediate filaments requires the presence of the neurofilament light subunit, NEFL, which expression is reduced in motor neurons in Amyotrophic Lateral Sclerosis (ALS). This study used zebrafish as a model to characterize the NEFL homologue neflb, which encodes two different isoforms via splicing of the primary transcript (neflbE4 and neflbE3). In vivo imaging showed that neflb is crucial for proper neuronal development, and that disrupting the balance between its two isoforms specifically affects NF assembly and motor axon growth, with resulting motor deficits. This equilibrium is also disrupted upon partial depletion of TDP-43, a RNA binding protein that is mislocalized into cytoplasmic inclusions in ALS. The study supports interaction of NEFL expression and splicing with TDP-43 in a common pathway, both biologically and pathogenetically. Copy rights belong to original authors. Visit the link for more info

Dr. Lorenzo Norris is an Associate Professor of Psychiatry and Behavioral Sciences at George Washington University, and the host and creator of the MDEdge Psychcast podcast. Palliative psychiatry for patients with Amyotrophic Lateral Sclerosis (ALS). Finding meaning in endings. “End of life does not result in a lack of meaning.” How maintaining the spirit of curiosity prevents mistakes and prevents a doctor from falling into simple pattern recognition. "Back then the idea of a black male wanting to be a physician . . . that's just a moonshot."Transcript

Warren Osborn is a serial entrepreneur, advisor, philanthropist, investor, and an expert in developing manufacturing and marketing consumer products. He has invested in over 65 companies including Stance, Omniture, Skull Candy, Workfront, Fusion-io, Jamba Juice, and more. Warren is a recipient of the American Red Cross Family Award for aiding an injured parachutist trapped on a dangerous cliff. He is also one of the founding members of the Utah Angels, an investment team of experienced serial entrepreneurs. In this episode… Starting and managing 11 successful businesses is not easy for most entrepreneurs. In fact, very few people can boast of such an accomplishment. However, for Warren Osborn, having the right strategies can push you to great heights and make you very successful. He uses a couple of winning principles that he shares with other entrepreneurs looking to grow their business. Warren also strongly believes that entrepreneurs can learn a lot by allowing themselves to go through tons of failure. It teaches them great lessons and how to pivot themselves out of such situations the next time they happen. His biggest attributes for starting & successfully managing 11 businesses are speed, passion, and a great desire for solving people's problems. In this episode of Buy Box Experts, Warren Osborn joins host Eric Stopper to share his great insights and advice for starting profitable businesses. He talks about how his inventions have seen him grow his businesses to millions of dollars, how he helped a company save $30 million, and how he is constantly looking for a cure for his Amyotrophic Lateral Sclerosis (ALS) diagnosis. Stay tuned.

Living Your Life with Purpose with Jodi O’Donnell-Ames  Amyotrophic Lateral Sclerosis (ALS), or Lou Gehrig’s Disease, is a neurological disease that takes a heavy toll on those who are diagnosed with it, as well as their families. Jodi O’Donnell-Ames came to understand how difficult it was when her husband was diagnosed with ALS. As Jodi cared for both her husband and her 2-year-old daughter, she found that there was a serious lack of resources for children whose parents were diagnosed with ALS. When her husband, Kevin, died in 2001, Jodi knew that she had to keep fighting, so she served as director of communications for the ALS Hope Foundation in Philadelphia from 2001–2003. While working there, she met Warren Benton Ames, whose wife Tina had passed away from ALS in 2000. Warren and Jodi married in 2003, and she became the mother of Ames’ two children. Inspired by the strength of their united family, this led her to found Hope Loves Company, the only non-profit organization in the country dedicated to providing education and emotional support for children and young adults who had or have a loved one battling ALS. Join us every other week on Women's Wealth: The Middle Way®, a radio show aimed at helping women navigate questions about work, money, and family. You can find us on your favorite podcast app, including , , , . See you in two weeks! Helpful Links: Women’s Wealth: The Middle Way® Glen Eagle Hope Loves Company   ALS Association        

Tune in to learn more about VA claims for Multiple Sclerosis (MS) and Amyotrophic Lateral Sclerosis (ALS). CCK attorneys provide an overview of each condition, how to get them service-connected, and how to build yourself a strong case for VA disability compensation. Follow us on social media: YouTube - http://bit.ly/CCKYTL Facebook - http://bit.ly/CCKFBL Instagram - http://bit.ly/CCKINL Twitter - http://bit.ly/CCKTL

Dr. Shelly Hoover is a wife, mother, grandmother, daughter, sister, and friend. She’s a veteran, author, educator, and advocate. It’s what she does. It’s who she is. In 2013, her neurologist told her that she only had two to five years to live. After a year of trying to figure out what was slowly happening to her body, Shelly was diagnosed with Amyotrophic Lateral Sclerosis (ALS) or Lou Gehrig’s disease. Some call it that Ice Bucket Challenge disease. From shellyhoover.com, “whatever you call it, it’s a fatal diagnosis with no effective treatment or cure. Yet I have much to live for and I’m determined to live in gratitude and joy regardless of circumstance. I feel alive when while I’m encouraging others to live their best life.” - Tony interviews Shelly about their shared experience running around a middle school track to help motivate kids, and raise money for the school, and how to make the event bigger, and better in the future, only to find that a few short months later, Shelly would begin to recognize the initial symptoms of what would eventually be diagnosed as ALS. - Shelly has also written a book, Timeless Sisters, available on Amazon https://amzn.to/38fiMuJ The book is about three strong women, Janene, Cora, and Amadahy, who live in the same North Carolina town centuries apart. Janene, a modern-day high school teacher, loses her career and identity in the face of a devastating illness. Cora, an enslaved person during the Civil War, flees the Yarbrough plantation after her family is murdered. She finds refuge at Mama Hattie’s house only to encounter the killer years later. Amadahy, a Cherokee before the European invasion, loses a child and her husband leaves. She finds an unlikely love while on a river adventure and returns to find trouble at home. A sacred, maternal talisman connects the three women as they search for lasting peace. Follow this fast-paced, emotional journey to the collective sisterhood at the river. The book has received phenomenal reviews from both critics, and readers alike. You can learn more about Shelly at http://shellyhoover.com - Tony's new best selling book "He's a Porn Addict...Now What? An Expert and a Former Addict Answer Your Questions" is now available on Kindle. https://amzn.to/38mauBo - Tony Overbay, is the co-author of "He's a Porn Addict...Now What? An Expert and a Former Addict Answer Your Questions" now available on Amazon https://amzn.to/33fk0U4. The book debuted in the number 1 spot in the Sexual Health Recovery category and remains there as the time of this record. The book has received numerous positive reviews from professionals in the mental health and recovery fields. - The book tackles tough questions with answers from both the expert and the addict's point of view. Tony, a licensed marriage and family therapist, and creator of The Path Back, an online pornography addiction recovery program that has helped hundreds of people overcome turning to pornography and other compulsive sexual behaviors as a coping mechanism, and Joshua Shea, former addict, and author of the book “The Addiction Nobody Will Talk About” read their respective answers to questions such as "Finding out he's addicted to porn has turned me off to sex completely, what should I do?" And "How much do we tell the kids?" And "Does this mean that God is mad at me, or doesn't love me?" - Reviews include: "This is the most helpful book for porn addicts and the people who (still) love them. One of the most courageous and timely books to help with a widespread and almost never talked about epidemic that is ruining marriages, careers, and lives. It will give hope to millions of people who are addicted to pornography. -- Mark Goulston, MD, FAPA, Author of Just Listen Discover the Secret to Getting Through to Absolutely Anyone. - You can learn more about Tony's pornography recovery program The Path Back by visiting http://pathbackrecovery.com And visit http://tonyoverbay.com and sign up to receive updates on upcoming programs, and podcasts. - The Virtual Couch is sponsored by http://Betterhelp.com/virtualcouch Betterhelp.com is the world's leading provider of online therapy. Their mission is to make professional counseling accessible, affordable, and convenient, so anyone who struggles with life's challenges can get help, anytime, anywhere. Head to http://betterhelp.com/virtualcouch for 10% off your first month of services

Curcumin (curcuma longa linn) - a polyphenol compound extracted from the spice turmeric—offers multiple biological activities. Research has pointed to the potential benefits of curcumin, as an associated therapy in oxidative stress diseases, such as neurological disorders. Curcumin, Hormesis, and the Nervous System, a research paper published in the October 2019, issue of the journal Nutrients, notes that, "there is growing evidence indicating that oxidative stress contributes to the etiology and the progression of neurodegenerative diseases, such as Alzheimer’s Disease (AD), Parkinson’s Disease (PD), Amyotrophic Lateral Sclerosis (ALS) and Multiple Sclerosis." However, the same research also points out that, "evidence-based medicine has clearly demonstrated the lack of any therapeutic effect of curcumin to contrast the onset or progression of neurodegeneration and related diseases."With advanced age, the effects of oxidative stress on brain function, known as neuro-inflammaging, has taken center stage in a search for compounds like curcumin that might offer good therapeutic treatment options. Italian researchers focused on the evidence related to the "hermetic effects" of curcumin relative to neuro-cognitive diseases. Hormesis is, "a term used by toxicologists to refer to a biphasic dose response to an environmental agent characterized by a low dose stimulation or beneficial effect and a high dose inhibitory or toxic effect."One large issue with the use of curcumin as an adjunct to therapy or a stand-alone compound is its hydrophobic property: being poorly soluble in water. "The poor intestinal absorption, structural instability, limited blood brain barrier penetration, and rapid degradation of curcumin in the body limits the potential, as a therapeutic agent in clinical trials," according to the Italians.Therefore, note the researchers, "an important aspect for the development of curcumin as a novel "nutraceutical’’ formulation deals with obtaining an increased bioavailability and physiological stability and solubility of this compound in animal models and humans."Much of the scientific interest has to do with curcumin’s potential to affect the central nervous system and protection from beta amyloid plaque—a prerequisite to neuro-degenerative diseases like Alzheimer’s.While curcumin is a natural product, it’s not without potential safely concerns, such as a potential toxic effect though its interaction with drug metabolism enzymes. One such interaction involves the issues associates with curcumin concurrent with tamoxifen, an antagonist to estrogen receptors, which is used as an adjuvant therapy in women with breast cancer."Furthermore, note the Italian researchers, curcumin has been shown to pose some adverse effects to the liver, under certain circumstances at high doses.Yet, the researchers conclude that, "with regard to the potential clinical efficacy of curcumin, there are several pre-clinical data in the literature confirming that curcumin possesses neuroprotective and cognitive-enhancing properties that may help delay or prevent neurodegenerative diseases."The best advice is to take Buddha’s recommendation and, "be moderate in all things." Check with your doctor first.

On this episode of My OT Journey Podcast student influencers Andrew Wells, of Utica College in Utica, NY and Olivia Kuehler, of the College of St. Mary in Omaha, NE reach out to Mrs. Jackie Warmuth an OT practitioner who uses eco-therapy in treating veterans who are transitioning to civilian life after serving our great country. Jackie has been working with the military population for 8 years and shares how much they have changed her life. Working with this population, Jackie shares the importance of gaining trust from your client. Jackie's eco-therapy approach to treating Veterans will be a well attended topic at the AOTA conference in Boston. In this episode Olivia Kuehler, OTS and Andrew Wells, OTS interview Jackie Warmuth OTR/L, Director of Rehabilitation @ Sitrin Rehabilitation Center  Jackie earned her B.S. from Utica College in 1990. A UC Alumna, Jackie has maintained a strong relationship with the UCOT program and has been extremely successful. Her dedication to the program includes teaching several classes such as facilitating specific units and labs, Case-Informed Discussions, and educating students as a fieldwork educator. Jackie is currently the director or rehab at Sitrin Health Care Center in Utica, NY. I am lucky enough to learn at such a beautiful facility that treats patients with neurodegenerative conditions such as ALS and Huntington's disease. The Neuro Care Center is the first and only of its kind in Upstate New York, providing comprehensive care to individuals with Huntington's Disease and Amyotrophic Lateral Sclerosis (ALS), two diseases that have no cure and no treatment to slow their progression. This facility treats any patients needing medical rehabilitation as well as the growing military rehabilitation program that Jackie plays a huge role in.   

Why You Should Listen: In this episode, you will learn about the importance of Indoor Environmental Quality in recovering from chronic illness and optimizing health. About My Guest: My guest for this episode is Michael Schrantz. Michael Schrantz, CIEC, CMI, ABI, BPI-BA/EP is the Founder and operator of Environmental Analytics, LCC, a comprehensive indoor environmental quality consulting company that covers a wide range of environmental assessments for the residential, commercial, and medical sectors. Mike has over 22 years of active indoor environmental quality & building science experience. He has been involved in over 4300 related projects expanding across the globe. His work includes identification of harmful indoor environmental contaminants, publication of spore trap analysis and MSQ-PCR methods, the co-authoring of remediation and prevention protocols, and countless hours in consulting efforts for thousands of clients around the world. He is a Council-certified Indoor Environmental Consultant (CIEC), a Council-certified Microbial Investigator (CMI), an Asbestos Building Inspector (ABI), and a Building Professional Institute-Building Analyst/Envelope Professional (BPI-BA/EP). He is on the board of the International Society for Environmentally Acquired Illness (ISEAI). He is on the Indoor Environmental Professionals Panel of SurvivingMold.com. He works with clients dealing with Chronic Inflammatory Response Syndrome (CIRS), Mast Cell Activation Syndrome (MCAS), Lyme Disease, Multiple Chemical Sensitivity (MCS), Small Intestinal Bacterial Overgrowth (SIBO), Pediatric Acute-onset Neuropsychiatric Syndrome (PANS), Pediatric Autoimmune Neuropsychiatric Disorder Associated with Streptococcal Infections (PANDAS), Amyotrophic Lateral Sclerosis (ALS) and Alzheimer’s Disease (AD). He is the host of IEP Radio where he "connects the dots between your health and home". Key Takeaways: - What is an IEP and the scope of their work? - What screening tests can be done before contacting an IEP? - What are the ERMI and HERTSMI-2? - Do the ERMI and HERTSMI-2 paint an accurate picture? - What is the best way to collect samples for the ERMI/HERTSMI-2? - Is there value in testing the environment for mycotoxins? - What does a "boots on the ground" inspection consist of? - What is the impact of outside mold levels on indoor mold testing interpretation? - Can personal belongings be salvaged? - Do remediations work or is moving a better option? - What is the contribution of an HVAC system or related ducting to poor indoor air quality? - Can fogging solutions or essential oils be appropriate tools? - What is the role of limbic system retraining in creating a better host-environment relationship? Connect With My Guest: http://EnvironmentalAnalytics.net http://IEPRadio.com Related Resources: ISEAI Development of an Environmental Relative Moldiness Index for US Homes Interview Date: September 3, 2019 Transcript: To review a transcript of this show, visit http://BetterHealthGuy.com/Episode104 Additional Information: To learn more, visit http://BetterHealthGuy.com. Disclaimer: The content of this show is for informational purposes only and is not intended to diagnose, treat, or cure any illness or medical condition. Nothing in today's discussion is meant to serve as medical advice or as information to facilitate self-treatment. As always, please discuss any potential health-related decisions with your own personal medical authority.

ALS, commonly known as Lou Gehrig's disease, is this week's topic of conversation. Hear from Swedish's Dr. Michele Arnold with guest host Mary Renouf and OM Media blogger Sunny Brous Erasmus as they discuss this disease for ALS awareness month.

Because HDAC4 closely resembles the structural component of the superfamily of histone deacetylases, in might be assumed it functions to catalyze the removal of LYS bound acetate. But since HDAC4 does not contain the catalytically necessary TYR-OH but rather an HIS-imidizole it has no deacetylase enzymatic activity. However HDAC4 does interact with other proteins and the net result is protective of skeletal muscle atrophy and motor neuron degeneration in a murine mutant human SOD1 model of Amyotrophic Lateral Sclerosis (ALS). This Authentic Biochemistry podcast episode reveals once again that specificity in time and space with coordinated expression of biochemical species will be more complicated than previously reported once a sharper lens is used to examine the disease pathology at the biochemical/molecular level. --- Support this podcast: https://anchor.fm/dr-daniel-j-guerra/support

Founded with the mindset of combating diseases that pharma companies have failed to treat, Denali Therapeutics is currently working on therapies for Alzheimer’s, Parkinson’s and Amyotrophic Lateral Sclerosis (ALS). The company has 13 large and small molecule programs across various stages of development and two strategic pharmaceutical relationships. Denali believes that new insights into genetics and biology offer, for the first time, the opportunity to discover and develop medicines for neurodegenerative diseases. See acast.com/privacy for privacy and opt-out information.

The printmaker and artist Jon Fasanelli-Cawelti has a solo exhibit entitled “Atlas” on display at the Muscatine Art Center. Consisting of over 40 large-scale drawings and prints, the work in this show was created over the past five years despite — and perhaps because of — Jon's diagnosis of Amyotrophic Lateral Sclerosis (ALS), also known as Lou Gehrig's disease.

The printmaker and artist Jon Fasanelli-Cawelti has a solo exhibit entitled “Atlas” on display at the Muscatine Art Center. Consisting of over 40 large-scale drawings and prints, the work in this show was created over the past five years despite — and perhaps because of — Jon's diagnosis of Amyotrophic Lateral Sclerosis (ALS), also known as Lou Gehrig's disease.

In this episode of Keto Talk, Jimmy and Dr. Will Cole answer your questions about Long-Term Keto Makes You Gain Weight, Blood Sugar Goals, Pre-Surgery Sugar Drink, Calorie Balance, And Low Ketones From Keto-Adaptation vs. Being Out Of Ketosis, and more! Subscribe via: Apple Podcasts | Google Play | RSS | Android COUPON CODE JIMMY FOR $50 OFF Highlight Quote:  “What I've seen is that keto can slow the progression of autoimmune conditions. It doesn't mean it will cure everyone's condition, but it is surely a better way to eat for your health.” -Dr. Will Cole GET A $39 BOTTLE OF OLIVE OIL FOR JUST A BUCK GET YOUR $39 BOTTLE FOR JUST $1 NOTICE OF DISCLOSURE: Paid sponsorship We begin this week's show by talking about this site sent in from our listener Jim – Sneaky Sugar website THIS WEEK’S HOT TOPICS:  What’s up with the white/yellow coating on my tongue ever since I started eating keto? Is any clinical or anecdotal evidence of a Ketogenic diet helping to reverse vitiligo? If I'm allergic to eggs and have a dairy sensitivity, how do I find keto-friendly fat to add to my meats that aren’t loaded with soybean and canola oil? Why does adding in intermittent fasting to my keto protocol lead to headaches? Does keto play any role in the improvement of the symptoms associated with having Amyotrophic Lateral Sclerosis (ALS)? 12 keto diet horror stories that will make you think twice before trying it If You Want to Save the World, Veganism Isn’t the Only Answer Want a healthier heart? Eat a steak How the Keto diet ‘could protect against Alzheimer’s’ – but is it really good for you? TIME FLIES: U.S. ADULTS NOW SPEND NEARLY HALF A DAY INTERACTING WITH MEDIA STUDY: Hospitals Lead by Poor Example: An Assessment of Snacks, Soda, and Junk Food Availability in Veterans Affairs Hospitals BONUS STUDY: Did eating starchy foods give humans an evolutionary advantage? BECOME A NUTRITIONAL THERAPY PRACTITIONER Sign up by September 2018 for the 9-month program NOTICE OF DISCLOSURE: Paid sponsorship Your Questions: – Traci asks, "Is there any truth to what my functional medicine doctor told me that long-term keto will make you gain back all your weight eventually?" – Starr asks, "What is a healthy blood sugar level to be aiming for if I am on a ketogenic lifestyle? Does it vary by age?" – "Is there an alternative to the sugary swill they require pre-surgery for people who eat keto?" Judy asks – "How do you best balance the calories on keto to keep hunger at bay, maintain therapeutic ketones, and lose weight?" Cathy asks. – Barry writes into to the Keto Talk mailbox to ask, "How do you know if low ketone levels are due to efficient keto-adaptation vs. being kicked out of ketosis?" MAKE KETO EASIER WITH FBOMB NOTICE OF DISCLOSURE: Paid sponsorship Highlight Quote: “There are so many options for adding good oils and fats to your diet that don't include industrial, low-grade inflammatory fats like canola oil or soybean oils.” – Jimmy Moore THE PERFECT KETO SUPPLEMENT USE COUPON CODE LLVLC FOR 15% OFF NOTICE OF DISCLOSURE: Paid sponsorship WORLD’S 1ST REUSABLE BREATH KETONE ANALYZER NOTICE OF DISCLOSURE: Paid sponsorship Apple Podcasts reviews LINKS MENTIONED IN EPISODE 129 – SUPPORT OUR SPONSOR: Track your sleep at BioHackingRing.com (COUPON CODE JIMMY FOR $50 OFF) – SUPPORT OUR SPONSOR: The world’s freshest and most flavorful artisanal olive oils. Get your $39 bottle for just $1 – SUPPORT OUR SPONSOR: Staying in ketosis just got easier – Your new keto-diet ally (Enter MOORE15 at checkout for fifteen percent off your first order.) – SUPPORT OUR SPONSOR: Drop an FBOMB for the freshest, high-quality fats from JimmyLovesFBomb.com (Get 10% off your first food order with coupon code “JIMMYLOVESFBOMB”) – SUPPORT OUR SPONSOR: Jump start your ketogenic diet with PerfectKeto.com/Jimmy (USE PROMO CODE LLVLC FOR 15% OFF) – KetoWhiteBoard.info – Jimmy Moore from “Livin’ La Vida Low-Carb” – Dr. Will Cole D.C. from DrWillCole.com  

Steve and Caleb are back and in this episode, they are back to discussing science straight out of the gate. Steve has been reading research about Amyotrophic Lateral Sclerosis (ALS) and he talks a bit about that. This leads to a discussion on the balance of perfection and practicality in science. Sometimes it is hard to figure out when enough is enough when designing an experiment. Sometimes the benefit is not worth all of the work it will take. Next, the guys talk about some career options that are available with a biology degree. When Caleb and Steve were undergrads they weren't aware of all of the possible careers in biology. They also talk about presenting science at meetings. Steve is hoping to present his thesis research at an American Physiological Society meeting this year. Caleb also gives some advice on giving an interesting presentation. Finally, they end with some speculation on the role of robots in society. Inevitably, they get on the "will the robots take over the world?" debate and Caleb picks his evil robot apocalypse weapon of choice. This is a fun science filled episode, check it out! Website Facebook Instagram Twitter

I’m honored to share this Episode #42 of the Mother’s Quest Podcast, a special conversation released in conjunction with ALS Awareness Month with Mary Huffman. Mary is a wonder woman unlike any I’ve ever met, who relishes life with exuberance, and shares her love with everyone in her midst, even when facing the greatest of challenges. I’ve known Mary and her family, her husband Ted, and her two children Anna and Jonny, for the last eight years, where we’ve been sharing one week out of every summer at a paradise known to us as Bruin Woods, UCLA’s alumni family camp in Lake Arrowhead, California. But the last summer we came together, Mary arrived in a wheelchair, suffering from a mysterious set of symptoms which she later learned was a fast progressing form of Amyotrophic Lateral Sclerosis (ALS) also known as Lou Gehrig’s disease. ALS is a progressive, neurodegenerative disorder which has currently left Mary almost bedbound 24/7 . This diagnosis has been devastating, as you can imagine. But through it all, Mary has focused on trying to stay positive, continuing her life goal of helping others, and making memories with her family and friends. In our conversation, we explore all the ways in which Mary has lived with grace, positivity and optimism her whole life, and especially since her diagnosis, when instead of falling into despair, she has determined to “Stephen Hawking the crap outta this,” cherish every moment, especially with her children, and find ways to live her legacy. This conversation covers a lot of territory, including the inspiration of her mother, who taught her so much about helping people, a year abroad in Russia during the time of Gorbachev, becoming the first college graduate in her family and then continuing to Stanford’s business school, and her entrepreneurial endeavors creating adult coloring books to reduce anxiety, something she has learned to conquer. She gives us a challenge to commit to coloring each night before we go to bed to reap mental health benefits and invited us to contribute to her Master List of Life Tricks. And of course we talked about her family…especially her husband and children who she adores. It was such a blessing to have this conversation with Mary during a time when she had full use of her voice. And, although we didn’t know when we recorded that we would share it publicly on the podcast, we decided afterward that doing so could contribute to her legacy of helping others. And that, as you’ll learn when you listen, means everything to Mary. Mary has so many lessons to teach us.. I hope you’ll leave this conversation, as I did, with a deep appreciation for living your E.P.I.C. life to the fullest, finding the ways that you can help others with a generous spirit, facing any challenge that life brings you with tenacity and optimism, and remembering as Mary and her son Jonny say that there is always rain before a rainbow. I’m sending you and your family so much love Mary as we release this episode out into the world. I hope those of you listening will join me in sending positive thoughts and wishes. This episode dedicated by: Mary’s friend, Marcella Klein Williams. Topics Discussed in this Episode: UCLA’s Bruin Woods, the magical place where Mary and I, and our families, have spent the last eight summers and a favorite memory of mine of Mary there singing karaoke to her husband The fast-moving form of ALS Mary has, the inspiration she takes from Stephen Hawkings’ legacy, and how she hopes the fast-moving version will become the curable one The video “There’s Something About Mary” that her friends and family created for her and the custom “ALS Mom” and “Team Mary” T-shirts she and her supporters have had printed The inspiration of Mary’s mother to help people and the many ways her mother and Mary have opened their homes and extended kindness to others Mary’s approach to engaging with her children by spending time and listening to them, giving them permission to make mistakes, and helping them understand the ups and downs that come with life. Her adventurous life path, including becoming the first in her family to attend college, a year abroad in the then Soviet Union, graduate school in business at Stanford, and management consulting abroad. The ways Mary has built strong connections her whole life and a key piece of advice for how to handle criticism that has served her and her relationships well How stumbling on a coloring book of her mother’s led her to co-create adult coloring books with a friend, and how coloring can have the same benefits as meditation Mary’s experience battling anxiety and her strategy for defeating our “anxiety monster” How Mary got started creating “Mary’s Tricks for Life”, and the “Master List of Life Tricks” that we can all contribute to The E.P.I.C. snapshot moments that revolve around her children and why they mean so much This Week’s Challenge: Mary challenges us to: Try coloring 15 minutes each night before going to sleep. Check out the special coloring pages that Mary has created if you don’t already have your own favorites. Tale a look at the list of life tricks at Mary’s website and send in your own so she can add it to the Master List of Life Tricks. This List is part of Mary’s legacy, one way to help others now and in the future. Resources Mentioned in this Episode: Learn more about Mary from her blog, Ted and Mary and watch the video we mention (linked at the bottom of the page) “There’s Something About Mary” Mary’s adult coloring books available at Amazon. The Coloring Book Zone where you can find Mary’s and other great coloring books. Use the code MOMISGREAT to get 30% Off. The Master List of Life Tricks You can help Mary with her ALS medical expenses at her gofundmepage. UCLA’s Bruin Woods where I met Mary and I have spent one week out of every summer together with our families for the last eight years Announcements: Launched on Mother’s Day, my guest on the podcast, Graham Seabrook, and I invite you to create your own One Minute Mom Manifesto about what you want to claim or reclaim in your motherhood. Use video, photos, poetry or any other form of your choice to express what matters most to you and share on social media using the hashtag#OneMinuteMomManifesto. For more on the inspiration behind this idea, and why it’s so important that we claim and reclaim our whole selves in motherhood, tune into our episode on the podcast, link in the comments and at mothersquest.com/ep41-graemeseabrook The Podcast is Reaching a Milestone We almost have 20,000 Downloads!!! Pay the inspiration forward  Share the mothersquest.com/podcast with a friend! Spring into Your E.P.I.C. Life Clarity Coaching Package Spring is an amazing time to more fully seed the E.P.I.C. Guideposts in your life. I’m opening a limited number of one-on-one coaching spaces for a 90 day coaching package that includes bi-weekly hour-long coaching sessions where I will help you mindfully close the chapter of the last season, identify your vision for what’s ahead, set strategic action steps for moving forward, and provide inspiration and accountability along the way. Email me at julie@mothersquest.com to set up a free discovery call and learn more. Virtual Mother’s Quest Circle Pilot I’m excited to announce that the first founding Mother’s Quest Virtual Circle has been filled. If you’re interested in a future circle, and want to receive notice when the applications open again, please add your name to this wait list at http://mothersquest.com/virtualcircleapplication/ Help us Grow the Mother’s Quest Community If you’re finding value from the Mother’s Quest Podcast and would like to get more involved, please join us in the Mother’s Quest Facebook Group, help us find more like-minded mothers on a quest by spreading the word and sharing your favorite episodes, and make a donation or apply to dedicate an episode. You can also share your story on the Mother’s Quest Blog. Acknowledgements: A big THANK YOU to our “patrons” for helping to bring these conversations to myself and other mothers through financial and/or in-kind support: Desiree Adaway Rachel Steinman Katie Hanus Denise Barreto Sage B. Hobbs Samantha Nolan-Smith Jody Smith Emily Cretella Collette Flanagan Titilayo Tinubu Ali Carly Magnus Hurt Lizzy Russinko Suzanne Brown Mara Berns Langer Mallory Schlabach Katharine Earhart Jessica Kupferman Jen Jenkins Dohner Genese Harris Tonya Rineer Liane Louie-Badua Cristin Downs Erin Kendall Niko Osoteo Erik Newton Claire Fry Divya Silbermann Rachel Winter Caren and Debbie Lieberman Cameron Miranda Fran and David Lieberman Debbie and Alan Goore The Sustainable Living Podcast Support the Podcast If you’d like to make a contribution to Mother’s Quest to support Season Three of the Podcast and/or help provide coaching scholarships for mothers, follow this link to make a contribution. If you would like to “dedicate” an upcoming episode to a special mother in your life, email me at julie@mothersquest.com

“The big thing about PhD is learning how to express your ideas in a coherent manner and explain to people why it’s important, why we should research that.” Jon has spent more than a decade as a student on the University of Utah campus in pursuing his undergrad degree and now his MD/PhD. We talk about his time on the Men’s Basketball team and how he prepared for medical school while playing. He discusses his Amyotrophic Lateral Sclerosis (ALS) research and the new and upcoming announcement pertaining to his work. He shares his thoughts on what it was like to return to medical school after five years away while getting his PhD and finally, what the committee looks for when looking at MD/PhD applications.

Alzheimer's disease is the most predominant neurodegenerative disorder of our time, and is an imminent health crisis in countries like the United States, where 15 million people are expected to suffer from the disease by 2050.  Alzheimer's disease is an age-related disorder that causes brain shrinkage, memory loss, and eventually, death.  This week we discuss major paradigm shifts in Alzheimer's disease research.  For decades, Alzheimer's disease researchers have argued over what causes the disease.  Some suspected clumps of tau protein to be the main culprit in Alzheimer's, while others maligned amyloid beta as the villain.  Now, the field is largely united under the amyloid cascade hypothesis, but new evidence suggests that amyloid beta serves important immune functions.  This revelation that amyloid beta is protective is upturning Alzheimer's disease research as we know it, and brings new relevance to recent discoveries into the links between traumatic brain injury and the microbiome as they relate to Alzheimer's. Connor Wander and Maya Gosztyla sit down to discuss new developments in the field, and what recent Alzheimer's disease discoveries mean to patients, clinicians, and the public alike.  We also discuss practical strategies to delay Alzheimer's disease onset that we find effective or particularly promising.  All based on the research, of course!   Maya operates and writes for an Alzheimer's Disease education blog called AlzScience.  The AlzScience blog breaks down Alzheimer's disease concepts in simple terms, with great graphic illustrations and links for further reading.  It's a terrific place to start learning about Alzheimer's or other neurodegenerative diseases. For even further reading, I also recommend Alzforum.  Alzforum is a highly technical resource for Alzheimers disease scientists and anyone looking to keep up with the latest research.  Alzforum isn't all about Alzheimer's either- they keep tabs on all neurodegenerative diseases including Amyotrophic Lateral Sclerosis (ALS), Parkinson's Disease, and other forms of dementia.    Don't forget to check out Maya's introductory interview (Episode 11) or Connor's introductory podcasts (Episodes 2 and 5)!   Show notes We mentioned several key studies  in the podcast, which are listed below.    Keep an eye out for Maya's review on amyloid beta's protective immune functions! Brush up with a great AlzScience post on general Alzheimer's Disease Or check out a more detailed post about pericytes, one of the gatekeeper cells to the brain   Further Reading Here's Dr. George Bloom's review titled Amyloid-β and Tau: The Trigger and Bullet In Alzheimer's Disease Pathogenesis Here's the landmark paper that showed Amyloid beta particles clumping on brain infections   Here's the recent amyloid beta blood test study we mentioned.   Here's a great review in print about the crosstalk between Neurons and Microglia in AD! Here's a study on the MEND protocol- lifestyle changes that improve cognitive function. If we missed anything, or you'd like more information, feel free to contact SFS, or Maya at @sfromascientist and @AlzScience, respectively.   Any other questions?  Let us know!  We appreciate your feedback. You can now support the podcast at https://www.patreon.com/sfspodcast.  Many thanks to our past and present supporters!  Thanks to Plant Warrior for their support.  Use discount code SFS10 at checkout for 10% off your purchase of plant-based protein.

Mary explains what Amyotrophic Lateral Sclerosis (ALS), also referred to as Lou Gehrig's disease, is. She covers the diagnosis, disease progression, and the resources available to the families dealing with ALS. Mary also shares the latest research and new medications for treating ALS!

Mary explains what Amyotrophic Lateral Sclerosis (ALS), also referred to as Lou Gehrig's disease, is. She covers the diagnosis, disease progression, and the resources available to the families dealing with ALS. Mary also shares the latest research and new medications for treating ALS!

Today we will be discussing new literature regarding stem cells and their efficacy for conditions such as Multiple Sclerosis (M.S.), Amyotrophic Lateral Sclerosis (ALS also known as Lou Gehrig’s Disease), and Stroke.  We will try to present these findings from the perspective of exciting possibilities but also the reality and […]

Ahead on Biotechnology Focus Radio : Bellus Health back in the game with a new therapeutic asset, BC Cancer Agency scientists make two breakthrough discoveries, and RepliCel Life Sciences gets by with a little help from its friends. We have this and more in store for you on this week’s show. Welcome to another episode of Biotechnology Focus Radio. I’m your host Shawn Lawrence, here to give you a rundown of this week’s top stories on the Canadian biotech scene.   Our first story this week takes us to CALGARY, AB where a team of Canadian physicians and researchers are believed to be the first in the world to have used gene therapy to treat a patient with Fabry disease, a rare inherited enzyme deficiency that can damage major organs and shorten lifespan. Specifically, people with the disease have a gene called GLA that doesn’t function as it should; as a result their bodies are unable to make the correct version of a particular enzyme that breaks down a fat called Gb3. A buildup of Gb3 can lead to problems in the kidneys, heart and brain. In their experimental trial, the researchers led by Dr. Aneal Khan, a Alberta Health Services medical geneticist and member of the Alberta Children’s Hospital Research Institute, Cumming School of Medicine, University of Calgary collected a quantity of a Fabry patient’s own blood stem cells then used a specially engineered virus to augment those cells with copies of the fully functional gene that is responsible for the enzyme. The altered stem cells were then transplanted back into the patient on Jan. 11, 2017. While Dr. Khan says it’s too soon to say whether this therapy will ultimately be a long-term treatment for the disease, based on the team’s success in animal trials, he is hopeful it will be a beneficial to patients Dr. Jeffrey Medin, a researcher with the Medical College of Wisconsin and the project’s principal investigator, adds that the trial is a major step forward in treating inherited genetic diseases in adults. The treatment, which has been approved by Health Canada for experimental purposes, is also believed to be the first trial in Canada to use a lentivirus in gene therapy. In this case, the specially modified virus was stripped of its disease-causing capability and augmented with a working copy of the gene that’s responsible for the missing enzyme. The project is being funded by the Canadian Institutes of Health Research and the Kidney Foundation of Canada. The Queen Elizabeth II Health Sciences Centre in Halifax and the University Health Network in Toronto are also recruiting people with Fabry disease for the trial. In R&D news, a team of BC Cancer Agency scientists has made two exciting drug discoveries that could potentially allow for new approaches to target various cancers more specifically, through the exploitation of mutations found only in cancer cells and not normal cells. The first discovery, which has already led to a clinical trial, exploits the inability of BRCA1/2 deficient cancers to repair their own DNA. The second discovery is of a drug-like molecule that can alter the way cells translate genetic information into proteins. Both discoveries were made by Dr. Sam Aparicio, head of the Department of Breast and Molecular Oncology, and his research team at the BC Cancer Agency.The first success in this area is a discovery published in Nature Communications, where Dr. Aparicio’s team has discovered that the drug, CX-5461, originally developed for cancers of the blood and lymph system, can be repurposed as a drug treatment for breast cancer. Still early in its clinical development life cycle, CX-5461 has been shown through Dr. Aparicio’s latest work, to bind to the DNA of certain regions of the genome causing it to fold up and interrupt the DNA copying process. Thus, the compound is selectively active in tumours from patients with mutations in the BRCA1/2 gene, known to cause a strong familial predisposition to breast cancer, and account for approximately 15 per cent of the population with the disease. The study is currently in Phase 1 of a multi-centre clinical trial coordinated by Canadian Cancer Trials Group, which began in June of 2016. Phase two will accept even more patients to determine whether the activity found through preclinical studies is reflected in responses in patients. Both Dr. Aparicio and Dr. Karen Gelmon, senior scientist, medical oncologist and the clinical trial lead for the study add that if the trial is successful, they then hope to expand testing to other types of cancer in the near future. In addition to the CX-5461 findings, a second paper published in Nature Communications communicates the discovery of a different prototype drug, a compound called ‘T3’, engineered to alter the way that cells translate DNA, through splicing of RNA, into proteins. According to the researchers, this small, yet highly-potent drug-like molecule, currently in lab-testing, is being used to understand how different breast cancer cells might be susceptible to having RNA splicing interrupted. The drug molecule interferes with the molecular machinery that stiches gene sequences together to make fully functional proteins. Mutations in RNA splicing genes and defects in splicing have been found in diverse cancers, including breast cancer. The prototype drug molecules are allowing Dr. Aparicio and his team to seek out situations where cancer cells are uniquely susceptible to interference with RNA splicing. As alluded to, both drug development studies are currently centered in breast cancer treatment, but hope to expand to other types, including prostate and ovarian. Dr. Aparicio and his team’s work was supported with strategic funding from the BC Cancer Foundation. In Business new, two European firms are teaming up with Vancouver based regenerative medicine company, RepliCel Life Sciences Inc.to assist RepliCel in getting its commercial-grade RCI-02 dermal injector prototypes manufactured and tested. One of the partnering firms, AMI, is an Austrian manufacturer of medical technology based near the shores of Lake Constance, within easy reach of Germany and Switzerland. AMI develops, manufactures and distributes their medical products throughout the world. All of them are made according to the highest quality standards and enable doctors to take even better care of their patients. The second partner, Art of Technology (AoT), is based in Zurich Switzerland and is an independent contract developer specializing in the design, development and miniaturization of complex customer specific electronic devices and embedded systems for use in industrial, medical and space applications. The RCI-02 injector itself was designed with input from dermatologists, industrial designers, and electronic and medical device engineers to improve the delivery of a variety of injectables in a controlled, precise manner, removing the risks and uncertainties of injection outcomes currently resulting from manually operated, single-needle syringes. According to RepliCel president and CEO, Lee Buckler, it is the world’s first motorized injection device with programmable depth and volume, a built-in Peltier element for pre-injection anaesthetising, and interchangeable needle head configurations. It is designed to deliver a variety of injectable substances including cells, dermal fillers, drugs or biologics intradermally (dermis), subcutaneously (fat) or intramuscularly (muscle) via an array of needle configurations ranging from a single needle to a 16 needle configuration (4×4) on one head. Buckler adds that the execution of these agreements covers what RepliCel believes to be the final stages needed to prepare RCI-02 for a market authorization application in the form of a CE mark in Europe. The company hopes to have the device ready for a CE mark application and in the hands of a licensing and commercial partner next year. Our next story takes us to the Maritime provinces where the Terry Fox Research Institute is investing $5-million in support of New Brunswick researchers and their colleagues at other cancer centres in Canada to study how new precision medicine tools could improve, and potentially save the lives of patients diagnosed with the incurable cancer of the blood and bone marrow, known as multiple myeloma. The initiative is known as the Multiple Myeloma Molecular Monitoring (M4) Study, and Dr. Tony Reiman, a medical oncologist and professor at the University of New Brunswick, will lead the team, which comprises researchers and clinicians at multiple sites including Vancouver, Calgary, Toronto and Montreal. Dr. Reiman says that he hopes the five-year study will result in game-changing new approaches to identifying, treating and monitoring the disease in patients, including those who are at high risk of relapse. His team in Saint John will organize all the participating centres as well as conduct its own research and receive and bank specimens (blood and marrow) from the 250 myeloma patients that will participate in the project. Additionally, M4 study team members will use tests based on advanced techniques like immunoglobulin gene sequencing, multiparameter flow cytometry, PET scans, circulating tumour DNA analysis, and novel drug resistance assays to evaluate the patient specimens and other biosamples. Principal investigators at the partner sites are: Drs. Donna Reece and Suzanne Trudel, Princess Margaret Cancer Centre; Dr. Nizar Bahlis, University of Calgary; and Dr. François Bénard, BC Cancer Agency. Patients will be recruited by the study investigators at their own sites. Principal investigators Drs. Reece and Trudel (PM) explain their role in M4 study in the following audio. BrainStorm Cell Therapeutics Inc., a HACKENSACK, N.J.- based company developing adult stem cell technologies for neurodegenerative diseases, has signed an agreement with CCRM in the hopes of furthering its market authorization request for NurOwn®.  For our new listeners, CCRM is a Toronto-based company focused on developing and commercializing regenerative medicine technologies, specifically cell and gene therapies. Through the agreement, CCRM will help Brainstorm explore opportunities to access Health Canada’s early access pathway for treatment of patients with Amyotrophic Lateral Sclerosis (ALS).  If NurOwn® qualifies for Health Canada’s “Notice of Compliance with Conditions” pathway, it could be authorized in Canada for distribution in early 2018. Through the agreement, the company will work Patrick Bedford, manager of clinical translation and regulatory affairs at CCRM. Stacey Johnson (@msstaceyerin) , director, communications and marketing at CCRM and editor of Signals Blog discussed this deal recently via her regular Right Turn column Be sure to check it out at http://www.signalsblog.ca/right-turn-new-stem-cell-product-for-als-seeking-approval-in-canada/. For our final story, nearly a year since it’s failed KIACTA™ Phase 3 trial and subsequently being forced into pulling the plug on its KIACTA program, BELLUS Health is back from the brink as the Montreal-based company announced a new partnership and licensing deal with The NEOMED Institute to take over the development and commercialization activities for a potential new treatment for chronic cough. According to Bellus stakeholders,, this is a transformative transaction as this exclusive worldwide license agreement adds to the company’s pipeline a potentially best-in-class drug candidate, BLU-5937, an asset which was formerly known as NEO5937.  Its development through  the P2X3 antagonist program was initiated by AstraZeneca scientists in Montreal, and assigned to NEOMED in October 2012 when the NEOMED Institute was first launched. It was selected as a drug candidate to advance towards the clinic based on development efforts and extensive pre-clinical work in chronic cough done at NEOMED. According to Roberto Bellini, president and CEO of the company, the drug now going by its new name BLU-5937  will be a core focus of BELLUS’s drug development efforts. About the condition, Chronic cough is a cough that lasts eight weeks or longer and significantly impacts quality of life, with significant social (exclusion, embarrassment, difficulty speaking), physical (sleep deprivation, rib fracture, vomiting) and psychosocial (anxiety, depression) repercussions. It is estimated that in the U.S. alone, more than 2.7 million patients suffer from chronic cough that is not controlled by currently available medications. How BLU-5937 works to treat it, is it acts on a clinically validated target in the chronic cough pathway, the P2X3 receptor. Both the company and NEOMED believe BLU-5937 has the potential to become a best-in-class treatment option because of its superior potency and selectivity for the P2X3 receptor. These properties suggest BLU-5937 will be effective and less likely to cause a problematic side effect seen with less-selective drugs: taste disturbances that are significant enough to affect drug compliance. Under the terms of the agreement, BELLUS Health will pay NEOMED an upfront fee of $3.2 million, consisting of $1.7 million in cash with $1.5 million worth of BELLUS Health common shares (Approximately 5,802,177 shares). NEOMED will also be entitled to receive a royalty on net sales-based revenues. Additionally, in lieu of milestone payments, a certain portion of all other revenues received by BELLUS Health from BLU-5937 will be shared with NEOMED according to a pre-established schedule whereby the shared revenue portion decreases as the program progresses in development. Well that wraps up another episode of the Biotechnology Focus Podcast. We hope you enjoyed it. Be sure to let us know what you think, and we’re also always looking for story ideas and suggestions for future shows, and of course we’d love to hear from you as well, simply reach out to us via twitter @biotechfocus, or by email at the following email address  press@promotivemedia.ca. And remember, you can also listen to past episodes online via our podcast portal at www.biotechnologyfocus.ca . For all of us here at Biotechnology Focus, thanks for listening

We talk about Amyotrophic Lateral Sclerosis (ALS). Guest Keith Stattenfield.

We talk about Amyotrophic Lateral Sclerosis (ALS). Guest Keith Stattenfield.

Thanks to the recent popularity of the Ice Bucket Challenge, the subject of Amyotrophic Lateral Sclerosis (ALS) has received an enormous amount of media attention. On this week’s episode, Dr. Russell Blaylock talks about the physiological connections between all neurodegenerative diseases and includes steps one can take to treat and prevent the ravaging effects of these diseases.

Patrizia Longone, Dipartimento di Neurobiologia Molecolare IRCCS Fondazione Santa Lucia, Rome, ITALY speaks on "Central nervous system alterations in Amyotrophic Lateral Sclerosis (ALS), evidence from the SOD1G93A mouse model". This seminar has been recorded by ICGEB Trieste

Marie-France has lost her voice and can only move a jaw muscle because of Amyotrophic Lateral Sclerosis (ALS), also known as Motor Neurone Disease (MND) or Lou Gherigs Disease. In this 4 minute video she shows how, with a single switch and AssistiveWare's Proloquo, KeyStrokes and SwitchXS software, she accesses her Apple PowerBook computer and communicates with others. She explains how she continues to perform a pivotal role in the household by doing the shopping, managing the bank accounts and even designing her own web site. Marie-France lives in Paris, France.

Judy is a yoga teacher living in South Florida who has gained wide recognition for her unique ability to guide her teachers and students to achieve their full potential. In 2007, Judy met Beau MacVane, a strapping 6’4″ Army Ranger, who after returning home from his fifth tour of duty in Iraq, contracted Amyotrophic Lateral Sclerosis (ALS), also known as Lou Gehrig’s Disease. Beau asked Judy to teach him yoga so he could stay as strong and connected to his body as humanly possible as he fought his terminal illness. Over the next several years Judy watched in awe as Beau was able to use her instruction, and his determination, to battle the decline of his physical body. What arose was a mental focus and a self-awareness that changed them both. When Beau passed away, surrounded by his loving family and friends, he left with a peace of mind more powerful than any physical limitation. Judy’s passion in offering her skill to the military is dedicated to the Warrior Spirit of Beau MacVane and his family. *In This Episode* * Connected Warriors ( https://connectedwarriors.org/ ) Support this podcast at — https://redcircle.com/the-trauma-therapist-podcast-with-guy-macpherson-phd-inspiring-interviews-with-thought-leaders-in-the-field-of-trauma/donations Advertising Inquiries: https://redcircle.com/brands